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Abstract 
When proliferating mutated cells lead to the formation of a solid tumor, they will reach a point 
where part of the cancer cells outgrow their blood supply. These cells will be deprived of oxygen 
and are designated as “hypoxic”. Since oxygen plays a crucial role in the cytotoxicity of ionizing 
radiation (IR), hypoxic cells are associated with resistance to radiotherapy. Current radiotherapy 
protocols to partly overcome tumor hypoxia utilize fractionated irradiation, where a dose of IR will 
preferentially kill the normoxic cell population and the remaining cell population with a higher 
relative proportion of hypoxic cells will become reoxygenated by the microenvironment thereafter. 
As part of a repetitive process, reoxygenated cells will subsequently be killed by the next dose of 
a fractionated treatment schedule. Driven by technological progress and novel insights in 
radiobiology, clinicians increasingly use stereotactic body radiotherapy (SBRT), where one or a few 
high-dose fractions of IR are precisely delivered to the tumor without overly co-irradiating the 
healthy surrounding tissue. However, single or a few high dose fractions do not exploit the process 
of tumor reoxygenation. Therefore, reoxygenation or a reduction of the hypoxic tumor fraction 
by a combined treatment modality with a pharmaceutical agent is of high interest to reduce the 
required dose of IR and thereby further minimizing normal tissue toxicity. 
In this PhD project, we investigated two distinct hypoxia-modulating pharmaceutical compounds 
and their relevance for radiotherapy in extensive preclinical tumor animal studies. The hypoxia-
activated prodrug evofosfamide is bioreductively activated in tumor regions with a low oxygen 
concentration whereupon it acts as a DNA-alkylating cytotoxic agent. Thereby it specifically kills 
hypoxic tumor cells without considerably damaging healthy tissue. We demonstrated a synergistic 
effect of evofosfamide and IR in A549 non-small cell lung cancer (NSCLC) xenografts, whereas it 
remained completely ineffective in UT-SCC-14 head and neck squamous cell carcinoma (HNSCC), 
both in vitro and in vivo. Retrospective analysis revealed a lack of the cytochrome P450 
oxidoreductase (POR) in the irresponsive HNSCC cells. We and other groups identified that in 
addition to low oxygen concentrations, evofosfamide requires POR for its activation. SiRNA-
mediated knockdown of POR in evofosfamide-sensitive A549 cells rendered this cell line 
irresponsive to evofosfamide treatment. Based on these insights we recommend to investigate the 
therapeutic efficacy of combined evofosfamide and IR treatment for cancer patients with hypoxic 
solid tumors that are tested positive for POR expression. 
An alternative approach for pharmacological radiosensitization was evaluated with the 
hemoglobin-effector myo-inositol trispyrophosphate (ITPP). Systemic ITPP administration leads to 
a decreased hemoglobin-oxygen binding affinity and results in enhanced oxygenation of hypoxic 
tissue. By using a non-invasive luciferase-based in vivo hypoxia reporter assay, we demonstrated 
increased tumor oxygenation already two hours after ITPP administration. Tumor irradiation two 
hours upon ITPP injection resulted in significantly delayed tumor growth when compared to 
radiotherapy alone. Immunohistochemical analysis of γH2AX foci demonstrated increased IR-
induced DNA damage within initially hypoxic tumor regions after combined treatment with ITPP 
as compared to IR alone. Furthermore, we observed a direct relation between initial tumor hypoxia 
and ITPP-mediated radiosensitization. A549 NSCLC xenografts with high hypoxic fractions 
responded better to combined ITPP and IR treatment as compared to FaDu HNSCC with an initially 
low hypoxic fraction. SBRT leads to endothelial cell death and results in a depletion of the tumor 
vasculature. Interestingly, neoadjuvant ITPP treatment completely prevented the disruption of 
tumor blood vessels as determined by immunohistochemistry four days after irradiation. The 
pericyte coverage and absolute perfusion rate was higher after combined ITPP and IR treatment 
when compared to irradiated tumors without previous ITPP treatment. Consequently, ITPP-
mediated vascular protection prevented radiotherapy-induced tumor hypoxia. 
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Supplementary experiments in MC-38 syngeneic colorectal carcinoma (CRC) indicate an 
involvement of the adaptive immune system to the response to combined ITPP and IR treatment. 
Within all tested tumor entities, we identified the strongest ITPP-mediated radiosensitization in 
MC-38 cells, even though these allografts are only intermediately hypoxic. Extensive exploration
of the tumor microenvironment (TME) by immunohistochemistry (IHC) seven days after irradiation
confirmed ITPP-mediated vascular protection. Preserved integrity of the tumor vasculature after
combined ITPP and IR treatment was associated with an elevated infiltration of CD4+ T cells that
might positively contribute to tumor control. Further experiments will be required to unravel the
mechanistic implications of vascular protection and subsequent increase in immune-cell
trafficking.
As part of my PhD project, we implemented an image-guided small animal radiotherapy platform
in our group. CT-based treatment planning with Monte Carlo dose calculation, followed by static
or dynamic irradiation enables to precisely treat very small structures in animal models and is an
attempt to increase the translational relevance of preclinical radiotherapy research. To further
develop our promising results obtained with ITPP treatment of subcutaneous tumors, we
generated an orthotopic colorectal liver metastases (CLM) model. CLMs manifest in a high unmet
need for novel treatment strategies, as the golden standard - surgical resection - is not always
applicable. We demonstrated that selective intraportal injection of CRC cells yields a high rate in
liver metastasis formation. Highly selective irradiation of the right liver lobe is technically feasible
and can be delivered with acceptable healthy tissue involvement. We identified significant animal
weight loss and an impairment of liver performance biomarkers at single doses of 20 Gy and
higher. On the other hand, CLM irradiation with single doses of 15 Gy and lower was well
tolerated and resulted in dose-dependent tumor growth delay kinetics. Preliminary combined
treatment with ITPP indicated a radioprotective effect on the healthy liver that might underlie the
same mechanism as observed in the protection of the tumor vasculature. Cumulatively these
findings demonstrate that small animal image-guided radiotherapy of CLMs is feasible, accurate
and effective. Based on these results, we will further investigate the multimodal combination of
ITPP and SBRT in CLMs.
In summary, my PhD work demonstrates that modulation of tumor hypoxia is an attractive and
potent approach to increase the efficacy of radiotherapy. While evofosfamide requires the
abundance of oxidoreductases for its activation, ITPP acts independently of the molecular and
genetic background of a solid tumor. Overall, our results support the strong rationale to combine
ITPP with SBRT for clinical investigation in patients suffering from hypoxic solid tumors.
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1. Introduction
1.1 Cancer overview 
1.1.1 Cancer and carcinogenesis 
The human body is a complex organism consisting of approximately 4 × 1013 cells [1]. These cells 
harbour and constantly reproduce an individual’s genetic information (genotype). In a multistep 
process described as carcinogenesis, minimal molecular changes in the genetic information occur 
and may lead to cancer if they remain unrepaired. As such, cancer can be defined as an 
accumulation of genetic alterations that change the cellular fate and lead to uncontrolled cell 
division and proliferation [2]. Typically, simultaneous mutations of several genes in one cell are 
required to achieve neoplastic tissue growth [3]. Amongst the most frequently mutated gene 
categories involved in cancer formation are gain of function mutations in oncogenes and loss of 
function mutations in tumor suppressor genes. Oncogenes promote proliferation and survival of 
cells, whereas tumor suppressor genes dampen cell proliferation and promote apoptosis, a form 
of programmed cell death. [4-6]. In 90 – 95% of the cases environmental and lifestyle factors, 
e.g. cigarette smoking, sun exposure or environmental pollutants are responsible for the genetic
mutations that lead to cancer [7].
Cancer can either affect the blood system or form a tumor in solid tissue, i.e. in organs, muscles
or bones. Depending on the site of origin, tumors are further subclassified: carcinomas are tumors
formed by epithelial cells, whereas sarcomas affect the connective tissue, i.e. muscles and fibrous
tissue. If a tumor remains encapsulated in the tissue of origin it is defined as benign, whereas
invasive and metastatic tumors are described as malignant neoplasms. The concept of metastases
will be discussed later in this dissertation.
Behind cardiovascular disorders, cancer is the second most frequent cause of death with 14.1
million new cancer cases and 8.2 million cancer-related deaths worldwide in 2012. Incidence and
morbidity depend on the gender and countries development. Worldwide, the five most common
sites of cancer diagnosed in men are lung, prostate, colon & rectum, stomach and liver, whereas
the female population most frequently suffers from breast, lung, colon & rectum, cervix and
stomach cancer [8, 9].
1.1.2 Hallmarks of cancer 
Even though cancer is a highly versatile disease, Hanahan and Weinberg described the cancer cell 
genotypes as a manifestation of six underlying alterations in cell physiology that determine 
malignant growth and named them as “The Hallmarks of Cancer” [10]. Eleven years later and 
after tremendous progress in cancer research, the same authors complemented the list with four 
additional hallmarks [11]. Since then, these pivotal publications have been cited and discussed 
more than 15’000 times and serve as a general reference and inspiration for basic and applied 
cancer research. I briefly summarized the 10 Hallmarks of Cancer and potential therapeutic 
strategies to target the individual Hallmarks in Figure 1: 
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Figure 1 Schematic representation of the hallmarks of cancer and therapeutic strategies to tackle the 
individual hallmarks. Sustaining proliferative signalling is associated with enhanced production and 
release of growth-promoting signals in cancer cells, acquired by a number of alternative pathways. 
Autocrine proliferative stimulation, interaction with tumor-associated stroma and deregulated intracellular 
signalling are only some of the ways that cancer cells sustain proliferation. Cancer cells evade growth 
suppressors by acquired mutations in key tumor suppressor genes like TP53, which negatively regulate cell 
proliferation in the case of excessive genome damage or other intracellular stress. Cancer cells evolve 
numerous strategies to limit or resist cell death mainly by misbalancing pro- and anti-apoptotic signals. 
Enabling replicative immortality is another hallmark of cancer. Cells in healthy tissue usually pass 
through only a limited number of cell cycles, resulting in progressive telomere shortening and eventually 
senescence or apoptosis. On the contrary, cancer cells upregulate the expression of telomerase that 
maintains telomere length avoiding cell death. In order to sustain their neoplastic growth with nutrients and 
oxygen, cancer cells induce angiogenesis by increased expression of pro-angiogenic genes like vascular 
endothelial growth factor (VEGF) or fibroblast growth factor (FGF). This in turn causes normally quiescent 
vasculature to continuously develop new vessels. Cancer cells activate invasion and metastasis pathways 
mainly by alternating cell-to-cell and cell-to-ECM adhesion molecules. Certain mutations confer a selective 
growth advantage in cell subclones. Defects in so-called caretaker genes that detect, repair or inactivate 
damaged DNA lead to genome instability. Immune cells infiltrate almost every tumor and paradoxically 
some cell subsets enhance tumorigenesis and progression. Tumor-promoting inflammation is associated 
with attraction of pro-tumorigenic molecules, e.g. growth factors or pro-angiogenic factors to the tumor 
microenvironment. To fuel their increased proliferation rates, cancer cells can reprogram their energy 
metabolism from oxidative phosphorylation to anaerobic glycolysis and continue growing also under low 
oxygen concentrations. Tumors can evade immune destruction by recruiting immunosuppressive cells, 
such as regulatory T cells and myeloid-derived suppressor cells (MDSCs). 
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1.1.3 The tumor microenvironment 
The tumor microenvironment (TME) is a collective term for the cells and molecules surrounding a 
tumor, including the stroma, ECM, vasculature, immune cells and their respective physicochemical 
milieu. The heterogeneous composition of the tumor microenvironment is continuously adapting 
to evolving environmental conditions and oncogenic signals coming from the tumor [12]. Based 
on the composition and activation state of the individual components, the TME can either promote 
or restrict tumor growth [13]. In order to predict the fate of tumor progression, it is important to 
understand the components of the TME and their influence on the tumor. In the following 
paragraphs, I will summarize the fundamental components of the TME and their major 
characteristics. 
1.1.3.1 Cytokines and Chemokines 
Cytokines are small proteins released by cancer cells, immune cells or stromal cells. The molecular 
group of cytokines includes chemokines, interferons, interleukins and tumor necrosis factors. Their 
expression and secretion is regulated by tumor microenvironmental factors and genetic and 
epigenetic mechanisms [14]. Chemokines orchestrate the trafficking of immune cells and vascular 
endothelial cells in the TME and thereby affect tumor immunity, cell migration, cell survival and 
cancer progression [15]. Depending on the secreted chemokine signature, the infiltrating immune 
cells can be of pro- or anti-tumorigenic subtype [16, 17]. Likewise, chemokines can also directly 
affect cancer cells and either promote or limit their survival [18, 19].  
1.1.3.2 Cancer-associated fibroblasts 
A major component of the tumor stroma is represented by cancer-associated fibroblasts (CAFs). 
Their morphology is similar to myofibroblasts with large spindle-shaped mesenchymal cells but as 
opposed to normal fibroblasts CAFs are constantly activated and neither revert to a normal 
phenotype nor undergo apoptosis and elimination [20]. The transformation of normal fibroblasts 
into CAFs is caused either by direct mutations or upon secretion of growth factors, miRNAs or 
reactive oxygen species (ROS). Once activated, CAFs promote cancer progression and invasion 
through the induction of angiogenesis, inflammation and ECM-remodeling [21-24]. Furthermore, 
genetic and epigenetic changes in CAFs are evidently contributing to cancer progression and 
resistance to current therapies [25]. Even though current biomarkers are not fully satisfactory, 
CAFs were found to be present in most solid tumors, in particular in breast, prostate and 
pancreatic carcinoma [26]. Different studies indicate the potential of CAFs as predictive biomarkers 
for cancer therapy across different cancer types [27]. 
1.1.3.3 Immune cells 
Solid tumors are co-colonized by a plethora of immune cells with distinct functions. An extensive 
immunogenomic analysis of more than 10’000 tumors across 33 different cancer types revealed 
that the leukocyte fraction within the TME ranges between <10% and >90%. The same 
investigators identified six different clusters of immune signatures, aiming to summarize and 
simplify the complex interplay of tumor-infiltrating lymphocytes and their effect on tumor 
progression (Figure 2) [28].  
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Figure 2 Solid tumors are characterized by immune subtype into six different classes termed wound healing, 
IFN-γ dominant, inflammatory, lymphocyte depleted, immunologically quiet and TGF-β dominant. 
Classification of the tumor immune landscape serves as a resource for future targeted therapies against 
solid tumors [28]. 
1.1.3.4 Vasculature 
To maintain the nutrient and oxygen supply, cancer cells release pro-angiogenic factors that 
subsequently vascularize the tumor [29, 30]. In general, there are two subtypes of tumor 
vascularisation. Angiogenesis is the formation of new blood vessels from existing ones and 
vasculogenesis is the formation of new blood vessels after recruitment of endothelial cells from 
the bone marrow [31]. Depending on the released growth factors, angiogenesis can be further 
subdivided into sprouting angiogenesis, where new vessels are formed from pre-existing blood 
vessels and intussusceptive angiogenesis, where existing blood vessels split into two new blood 
vessels [32]. Chronic secretion of pro-angiogenic factors from solid tumors leads to an 
uncontrolled overproduction of new blood vessels and results in a structurally and functionally 
abnormal tumor vasculature. Tumor blood vessels are often leaky, dilated and interconnected with 
loosely attached or absent pericytes and basement membranes. Consequently, blood flow is 
spatially and temporally heterogeneous leading to interstitial hypertension, acidosis and hypoxia 
in the tumor microenvironment [33]. Hypoxia and acidosis in turn stimulate the secretion of pro-
angiogenic factors and further aggravate angiogenesis [34]. Vessel leakiness results in swelling 
and oedema in the TME and facilitates metastatic tumor dissemination [35]. Furthermore, the 
abnormal tumor vasculature negatively affects tumor treatment by different means. An inefficient 
blood supply impedes the delivery of chemotherapeutic agents to the cancer cells and in response 
to tumor hypoxia, cancer cells respond less to radiotherapy [33]. 
In summary, a multitude of reasons highlights the importance of vascular deregulation for 
malignant progression of solid tumors. Based on that, academic researchers and pharmaceutical 
companies gained interest in developing cancer therapies that target the tumor vasculature. 
Whether tumor vessels should be destroyed to starve the tumor and induce its shrinkage or 
whether tumor vessels should be normalized to reduce metastatic spread and improve the delivery 
of cytotoxic drugs is still under debate [36]. So far, approved anti-angiogenic therapy for cancer 
mainly attempts to neutralize VEGF, which is the most important pro-angiogenic molecule that is 
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overexpressed in the majority of solid tumors [37]. VEGF-targeting drugs, including the antibody 
bevacizumab and the tyrosine kinase inhibitor sorafenib have been approved for several cancer-
related indications but failed to show satisfactory results in overall patient survival [38, 39]. The 
paradigm is now shifting towards the preclinical evaluation of vasculature-normalizing agents, 
including chloroquine and ITPP [40, 41]. 
1.1.3.5 Hypoxia 
A tumor area is defined as hypoxic when its partial oxygen pressure (pO2) is lower than the pO2 in 
the surrounding healthy tissue. Theoretically, an exact pO2 threshold level that divides tumors into 
hypoxic or normoxic should not exist, because the oxygen demand in the human body is tissue-
dependent [42]. Nevertheless, the scientific community generally accepts oxygen levels below 2% 
(pO2= 15 mmHg) as hypoxic [43]. The oxygenation status of most solid tumors manifests in an 
extremely heterogeneous pattern of normoxic, mildly hypoxic and severely hypoxic areas. Tumor 
hypoxia can be further subdivided in acute (ischemic) and chronic (diffusion-limited) hypoxia. 
Acute hypoxia is a result of temporary obstruction or reduction of the blood low, whereas chronic 
hypoxia appears in tumor areas whose distance to the closest blood vessel is further than the 
maximal oxygen diffusion distance (100 – 200 µm) [44, 45]. To explain this heterogeneity it is 
important to understand how tumor hypoxia is induced. 
When proliferating mutated cells lead to the formation of a neoplastic tumor, they will reach a 
point where part of the cancer cells outgrow their blood supply. The decreased oxygen 
concentration in these cells will trigger signalling pathways to restore oxygenation. A family of 
heterodimeric transcription factors named hypoxia inducible factors (HIFs) plays a central role in 
cellular oxygen homeostasis. They consist of an oxygen-dependent alpha domain (HIF1α, HIF2α, 
and HIF3α) and a constitutively expressed beta domain (HIF1β) [46]. The activities of the alpha-
subunits are primarily regulated by post-translational hydroxylation of a proline residue in the 
oxygen-dependent degradation domain by prolyl hydroxylase domain proteins (PHDs). Proline 
hydroxylation targets the alpha subunits for proteasomal degradation by promoting their 
interaction to von Hippel-Lindau (VHL), a tumor suppressor with ubiquitin ligase activity [47]. At 
cellular oxygen concentrations below 1%, PHDs become inactive and HIF1α is consequently 
stabilized [48, 49]. A nuclear localization signal (NLS) in its C-terminal region enables rapid 
translocation of HIF1α into the nucleus, where it dimerizes with HIF1β and induces the expression 
of downstream target genes [50]. More than 60 HIF1 target genes, mainly affecting cell 
metabolism, cell survival and angiogenesis have been identified, including VEGF-A, the key 
regulator of tumor angiogenesis [51]. As discussed previously, constant secretion of VEGF by 
hypoxic tumors leads to the formation of a leaky and dysfunctional vasculature. The resulting 
irregularities in blood flow create hypoxic regions, which further aggravate VEGF secretion, 
leading to a vicious cycle of hypoxia and angiogenesis. 
Tumor hypoxia results in numerous pro-tumorigenic transformations, such as repression of DNA 
damage repair and genomic instability [52-54]. Moreover, hypoxia promotes a stem-like 
phenotype in the tumor cell population by maintaining cancer stem cells (CSCs) in an 
undifferentiated stem cell state, which enables self-renewal and continuous accumulation of 
genetic and epigenetic alterations [55, 56]. The selection and maintenance of CSC in the hypoxic 
TME further promotes malignant progression and therapy resistance [57]. An important aftermath 
of tumor hypoxia and increased HIF-signalling is the promotion of metastatic spread. Owing to 
the leaky and dilated tumor vasculature induced by hypoxia, escape of cancer cells from the 
primary tumor appears logical. Irrespective of the abnormal vasculature, hypoxia-mediated 
expression of HIF target genes that control immune suppression, invasion and migration further 
support early stages of metastases [58]. Tumor hypoxia is associated with increased secretion of 
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the matrix metalloproteinase MMP-1, an ECM-modifying protein that facilitates the extravasation 
of cancer cells from the primary tumor into the blood and lymphatic system [59]. Another HIF 
target gene involved in metastatic progression is lysyl oxidase (LOX), which was shown to post-
translationally modify the ECM in distant tissues to establish a microenvironment that enables the 
growth and survival of metastasized cancer cells [60]. High LOX-expression in primary tumors is 
associated with poor metastasis-free and overall survival in cancer patients [61]. 
Tumor hypoxia not only leads to malignant transformation and progression of cancer cells but 
also is responsible for treatment resistance, especially in combination with radiotherapy. These 
important aspects will be addressed later in my thesis. 
Figure 3 Most solid tumors are associated with a chaotic and unfunctional vasculature driven by constant 
release of VEGF as a result of tumor hypoxia. Vascular malfunction limits the oxygen deliver to cancer cells 
and thereby decreases their radiosensitivity [62]. 
1.1.4 Metastases 
Representing one of the hallmarks of cancer, metastases are the result of a biological multi-step 
process that triggers the dissemination of primary tumors to anatomically distant organs. Although 
the exact trigger that drives a cancer cell to become metastatic is still under debate, a multitude 
of factors have been shown to influence this malignant process. As mentioned above, tumor 
hypoxia is one of the key-drivers of metastatic spread. Nevertheless, other causative mechanisms 
must be accountable for metastases deriving from normoxic cancer cells. It is hypothesized that 
oncogenic mutations play an essential role for the initiation of the metastatic process [63]. Tumor 
hypoxia or mutations leading to deregulated TGF-β signalling are considered the most relevant 
metastatic triggers [64]. TGF-β induces epithelial-mesenchymal transition, in which epithelial cells 
acquire a mesenchymal phenotype, resulting in enhanced motility and invasion [65, 66]. Driven 
by transcription factors, including SNAIL, TWIST and ZEB, epithelial cells lose their cell junction 
proteins and reprogram their gene expression towards an invasive, mesenchymal phenotype [67]. 
Subsequent secretion of proteolytic matrix-metalloproteases (MMPs) degrades the extracellular 
matrix (ECM) and creates a path for metastatic cells to reach the systemic circulation. The 
accompanying abundance of growth factors and cytokines sustains the proliferation and survival 
of liberated primary tumor cells [68]. The leaky and chaotic tumor microvasculature described in 
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previous paragraphs, facilitates the lymphatic or blood vessels invasion. Consequently, circulating 
tumor cells (CTCs) face an inhospitable environment in the vascular circulation, caused by 
hemodynamic shear forces and the abundance of anti-tumorigenic innate immune cells [69]. It is 
estimated that less than 0.01 % of all CTCs survive in the circulation and successfully disseminate 
to distant organs [70]. The survival of CTCs is supported by blood platelets, which form platelet-
cancer cell clusters and thereby prevent immune cell recognition and further aid in attaching to 
endothelial cells and extravasating to distant tissues [71, 72]. The “seed and soil” hypothesis 
proposed by Stephen Paget in 1889, claiming that the distribution of metastases is not random, 
resulted in the pre-metastatic niche model. This is characterized by a plethora of bone marrow 
derived cells (BMDCs) that render the microenvironment of distant organ sites receptive to tumor 
growth by secreting bioactive molecules that remodel the ECM to accelerate cancer cell adhesion 
and invasion [61, 73, 74]. By inducing VEGF signalling, the BMDCs further help in overcoming 
angiogenic dormancy, an inability of metastasized cancer cells to proliferate due to insufficient 
vascularization [75-77]. Finally, by reprograming their gene expression, metastasized cells commit 
to mesenchymal-epithelial transition (MET) and continue to proliferate in the distant tissue [78]. 
While primary tumors are often curable by surgical resection and adjuvant therapy, metastatic 
lesions are usually incurable as a result of systemic spread [69]. As metastases have comparably 
low proliferation rates, they are relatively resistant to cytotoxic drugs targeting cell growth and 
division [77]. Moreover, metastatic lesions often acquire mutations that are molecularly distinct 
from the primary tumor and thereby do not respond to targeted therapy against the primary 
tumor lesion [79]. Based on the lack of curative treatment options, metastatic disease accounts 
for approximately 90 % of cancer-related deaths [80]. To overcome this dramatic fact, novel 
treatment strategies simultaneously targeting the tumor microenvironment and intracellular 
signalling pathways have to be investigated and implemented in current treatment protocols.  
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Figure 4 The main steps in the formation of a metastasis include a) progressive cellular transformation b) 
extensive vascularization to permit primary tumor growth c) local invasion of the tumor stroma d) 
detachment from the primary tumor, transport through vascular or lymphatic system and adharence in 
vessel walls e) extravasation to a secondary tissue, followed by f) proliferation in the metastatic site [81]. 
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1.2 Cancer diagnosis and imaging 
1.2.1 General aspects of cancer diagnosis 
In 2012, 14.1 million new cancer cases have been diagnosed worldwide. The incidence of newly 
diagnosed cancer patients is estimated to further increase due to population growth and aging 
[9]. In order to diagnose cancer, a plethora of invasive and non-invasive methods has been 
developed over the past centuries. Early diagnosis of malignant transformation is key for successful 
cancer therapy, because treatment of tumors that have not yet metastasized is more promising. 
Screening programs for supposedly healthy individuals with a specific risk for cancer development 
based on age, gender, lifestyle or genetic predisposition have evolved and play a vital role in early 
diagnosis. Depending on the surveyed tissue, diagnostic methods range from physical examination 
(breast, testis and skin), invasive imaging (colon and stomach), non-invasive imaging (breast, lung 
and ovaries) to specific biomarker detection (prostate, cervix and ovaries) [82]. Upon detection of 
a tumor, clinicians have to determine the malignancy of the neoplastic lesion. Apart from TNM-
staging that describes tumor size, lymph node involvement and metastatic spread, the malignancy 
is further examined by invasively collecting tumor biopsies and analyzing their genetic or 
proteomic signatures. The detection of cancer-specific biomarkers in liquid biopsies is an emerging 
and non-invasive approach to diagnose cancer or assess molecular changes of cancer cells during 
therapy. Extensive research is ongoing to reliably interpret the limited amount of tumor material 
in liquid biopsies [83]. 
In the following paragraphs, I will summarize some of the most relevant non-invasive tumor 
imaging modalities and specifically address the diagnostic tools to measure tumor hypoxia. 
1.2.2 Computed tomography 
In 1895 Wilhelm Conrad Röntgen discovered X-rays, a form of electromagnetic radiation with 
wavelengths between 0.01 and 10 nm. Only a few months after his discovery, the medical use of 
X-rays was probed to scan the wrist of a patient [84]. The interactions of X-rays with the human 
body are nowadays well known. As X-rays pass through the body, different organs and structures 
absorb them before they reach the detecting film. The absorption rate is tissue-dependent, i.e. 
bones with a high atomic density absorb more X-rays than soft tissue organs or the lungs. A 
conventional X-ray scan (radiograph) accordingly depicts the different tissues within a human body 
in two dimensions. Röntgen’s discovery was further developed and translated into computed 
tomography (CT), where rotating X-ray beams together with a digital detector generate cross-
sectional images that can be stacked together to provide a three-dimensional representation of 
the structures in the human body. CT scans are extensively used in clinical practice for cancer 
diagnosis and monitoring, as a prerequisite for treatment planning in radiotherapy and as a basis 
for functional imaging modalities (PET/SPECT). As tumors usually have a similar tissue density to 
that of the surrounding healthy organs, CT scans are often acquired after systemic injection of a 
contrast-enhancing agent to increase the visibility of tumors [85]. In the relatively novel field of 
image-guided small-animal radiotherapy researchers utilize cone-beam CT (CBCT) scanners, 
where the emitted X-rays form a cone-shape. This increases the scan area and enables to acquire 
volumetric images without a full gantry cycle. 
1.2.3 Magnetic resonance imaging 
Magnetic resonance imaging (MRI) is another frequently used medical imaging technique in the 
field of oncology. As opposed to CT imaging, MRI does not utilize ionizing radiation to generate 
a patient scan. Instead, the patient is exposed to strong, oscillating magnetic fields, which excite 
hydrogen atoms of water molecules in the human body. The rate at which excited hydrogen atoms 
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return to the equilibrium state determines the contrast between different tissues [86]. The return 
to the equilibrium state consists of longitudinal relaxation (T1) and transverse magnetization (T2). 
Depending on the tissue of interest, radiologists can acquire T1-weighted or T2-weighted scans 
by adjusting the scanning parameters [87]. As for CT imaging, contrast agents are an important 
measure to increase the visibility of neoplastic lesions in MRI scans. These contrast agents are 
usually based on paramagnetic gadolinium or superparamagnetic iron molecules that based on 
their structure and route of administration accumulate in specific tissues where they influence T1 
or T2 relaxation times and thereby enhance the tissue visibility [88]. In contrast to CT imaging, 
MRI scans can reveal additional physiological information. Advanced MRI techniques can for 
example monitor the circulation of body fluids by diffusion-weighted imaging (DWI) or perfusion-
weighted imaging (PWI). Furthermore, functional MRI (fMRI) measures oxygen concentrations by 
a method that I will describe in the paragraph “Methods to detect tumor hypoxia” [89]. 
1.2.4 PET and SPECT 
The information acquired from CT or MRI scans is sometimes not sufficient to detect or quantify 
a tumor. In this case, radiopharmaceutical agents specifically targeting the desired tissue can 
facilitate tumor diagnosis. Depending on the physical decay properties of the radionuclide it is 
either traced by positron emission tomography (PET) or single photon computed tomography 
(SPECT) and co-registered with a CT or MRI scan to obtain anatomical information. For PET-
imaging, patients are intravenously injected with a PET tracer containing a radionuclide that decays 
to a positively charged positron that thereupon annihilates with an electron in close proximity. 
Annihilation generates two opposing gamma rays that can be detected and processed by a circular 
PET detector. Subsequently the annihilation position can be reconstructed and overlaid with the 
anatomical scan. Finally, a three-dimensional scan showing the accumulation of the radiotracer 
gives detailed information about the location and size of the primary tumor and eventual 
metastases. The most widely used PET tracer in oncology is based on glucose (18F-FDG) and is 
taken up to a higher extent by cancer cells [90]. In SPECT-imaging, patients receive radiotracers 
that directly decay by gamma ray emission. Similar to PET scanners, SPECT-imaging detects, 
processes and reconstructs the gamma rays to pinpoint the localization of radiotracer 
accumulation. The most frequently used tracers in SPECT-imaging contain the metastable 99mTc 
radionuclide [91]. 
The main advantage of functional and metabolic imaging by PET or SPECT is the potential to 
detect small lesions and metastases that are usually not visible by conventional CT or MR imaging 
[92]. Furthermore, target-specific radiotracers can depict certain microenvironments (e.g. hypoxia) 
or extracellular receptors indicative of a malignant prognosis and progression [93, 94]. 
1.2.5 Methods to detect tumor hypoxia 
Tumor hypoxia is one of the major factors limiting the success of cancer therapy [95]. To improve 
clinical treatment strategies and provide measures for patient stratification a variety of invasive 
and non-invasive methods to detect and quantify tumor hypoxia were developed over the past 
decades. 
An invasive approach that measures tumor hypoxia are polarographic oxygen microelectrodes 
where thin needle sensors are directly inserted into the tumor and quantitatively determine the 
pO2 in real time. As these measurements depict spatial pO2 information, repeated measures in 
different tumor areas have to be performed in order to get an overview of the whole tumor. The 
invasiveness of this approach together with technical long-term instability and the development 
of non-invasive imaging methods have led to the discontinuation of oxygen microelectrodes in 
clinical practice [96, 97]. Another invasive method to detect tumor hypoxia is histological staining 
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of tumor biopsies. Excised tissues are either stained for endogenous hypoxia-specific biomarkers 
(e.g. HIF-1α and carbonic anhydrase IX (CAIX)) or for exogenously injected nitroimidazole 
compounds [98]. Nitroimidazoles, including its most prominent substance pimonidazole are a 
group of related compounds that are chemically reduced in areas of pO2 < 10mmHg and 
subsequently form irreversible adducts with unspecific proteins [99]. The disadvantages of 
histological hypoxia detection are invasiveness, spatial restriction and the relatively long processing 
time. As such, hypoxia characterization by histology is nowadays primarily used in preclinical or 
retrospective investigations. In clinical trials, tumor biopsies are also used for correlation of tumor 
hypoxia with a specific genetic landscape. Investigators could identify a 26-gene signature that 
predicts the benefit from hypoxia-modifying therapy in a specific type of cancer [100, 101]. 
Since all of the methods described above are invasive and relatively time consuming, the scientific 
and clinical community tends to favor non-invasive hypoxia detection methods. A frequently used 
approach are PET/CT scans with radiopharmaceuticals specifically targeting hypoxic tissues. Most 
tracers are derived from the nitroimidazole family of compounds and are radiolabelled with 18F 
(e.g. 18F-fluoromisonidazole (18F-FMISO) or 18F-fluoroazomycin-arabinofuranoside (18F-FAZA)) [102]. 
The radioactive PET tracers represent an additional burden of ionizing radiation for cancer patients, 
which emphasizes the importance of alternative non-invasive methods to detect hypoxia.  
A variety of functional MRI methods is suitable to non-invasively detect tumor hypoxia without 
the aid of radioactive tracers. Blood oxygen level-dependent (BOLD) MRI measures blood 
oxygenation on the basis of changes in the paramagnetic deoxyhemoglobin molecule. The BOLD 
effect is not strictly oxygen-dependent and also influenced by blood flow, hemoglobin levels and 
the state of the vasculature, a quantitative relationship to pO2 could not be proven [102, 103]. 
However, BOLD measurements showed significantly increased signals after carbogen treatment in 
patients [104]. Other fMRI methods that indirectly reflect tumor oxygenation on the clinical and 
preclinical level are dynamic contrast-enhanced (DCE)-MRI, diffusion weighted imaging (DWI)-MRI 
and electron paramagnetic resonance (EPR)-MRI [105-107]. 
 
1.3 Cancer treatment 
1.3.1 General aspects of cancer therapy 
The incidence of cancer patients is increasing worldwide and is projected to reach 19.3 million 
new cancer cases per year by 2025 [108]. The vast heterogeneity in cancer genetics, epigenetics, 
location, malignancy and stage requires a broad spectrum of independent or synergistic treatment 
approaches to cover the unique molecular features of each cancer patient. Depending on the 
individual diagnosis and regional healthcare guidelines, cancer patients are treated by surgery, 
chemotherapy, targeted therapy, immunotherapy, radiotherapy or a combination of different 
approaches. In the following paragraphs, I will summarize the rationale and application of the 
various cancer treatment modalities. 
1.3.2 Surgery and Chemotherapy 
Surgical resection of tumors is the oldest oncological discipline and is currently regarded as the 
only curative treatment strategy available. Driven by technical innovation and combinations with 
neoadjuvant or adjuvant therapies cancer surgery has reached a level of optimal local control and 
minimal surgical morbidity and mortality in almost all types of solid tumors [109].  
Chemotherapy is a cancer treatment that uses pharmacological compounds to target rapidly 
dividing cells with a curative or palliative intent. Since some healthy cells in the human body also 
have high proliferation rates (e.g cells lining the mucosal tissues), chemotherapy is often 
accompanied with side effects like nausea and diarrhea. Chemotherapeutic agents are often 
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combined with surgery or radiotherapy and based on their mode of action classified in different 
subgroups: 
Alkylating agents are electrophilic compounds that react with DNA or proteins to form 
irreversible covalent bonds, which subsequently impair DNA replication and transcription. DNA 
alkylating agents exert their effect independently of the cell cycle phase. Some of the most 
frequently used alkylating agents in oncology are cyclophosphamide, cisplatin and temozolomide 
[110].  
Antimetabolites interfere with DNA synthesis by either inhibiting the biosynthesis of 
deoxyribonucleotides for DNA replication (e.g. 5-fluorouracil) or by becoming fraudulent 
substrates for DNA polymerases (e.g. gemcitabine) [111]. Antimetabolites usually affect cells in 
the S phase of the cell cycle. Other frequently used antimetabolites for cancer therapy are 
methotrexate, doxorubicin or bleomycin. 
Microtubule-interfering agents, also called microtubule-targeting agents or spindle poisons act 
on the cell spindle during mitosis by either stabilizing microtubule polymers (taxane class, e.g. 
paclitaxel) or by disrupting microtubule polymerization (vinca alkaloids class, e.g. vincristine) [112]. 
Dysregulated microtubule function results in cell cycle arrest and subsequent apoptosis. 
Topoisomerase inhibitors interfere with topoisomerases, which are enzymes that prevent DNA 
supercoiling and entanglements during DNA replication and transcription. Lack of topoisomerase 
activity results in stalled polymerases or formation of abnormal nucleic acid structures that 
eventually induce cell cycle arrest in the G2 phase [113]. Some of the most frequently used 
topoisomerase inhibitors for cancer therapy are irinotecan or etoposide. 
1.3.3 Molecularly targeted therapy 
Unlike in chemotherapy where all rapidly dividing cells are affected, targeted therapy limits the 
growth of cancer cells by specifically interacting with molecules or pathways required for 
carcinogenesis, by inducing apoptosis or by modifying the function of proteins that regulate gene 
expression. The rationale of personalized medicine is to identify patients that could benefit from 
a specific targeted therapy based on the expression of molecular markers [114]. At the same time, 
patients unresponsive to a specific treatment can be given different treatment modalities. Based 
on that, molecularly targeted therapy is associated with improved efficacy and decreased toxicity 
in cancer patients. Numerous molecularly targeting drugs with different modes of action are 
approved for the treatment of cancer patients. So far, they mostly consist of small molecules like 
the tyrosine kinase inhibitors (e.g. imatinib) and monoclonal antibodies like anti-angiogenic drugs 
(e.g. bevacizumab). 
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Figure 5  Schematic representation of cellular targets for molecularly targeted therapies. Potential targets 
and currently approved drugs include growth factor receptors (e.g. gefitinib), non-receptor signalling 
molecules (e.g. everolimus), inhibitors of apoptosis proteins (e.g. bortezomib), epigenetic regulators (e.g. 
vorinostat), metabolic modulators (no drugs on the market), angiogenesis regulators (e.g. bevacizumab) 
and immune checkpoint proteins (e.g. nivolumab). Figure adapted from Huang M et al [115]. 
1.3.4 Immunotherapy 
The immune system not only recognizes and eliminates malignant cancer cells, but also plays a 
critical role in promoting tumor progression. The dual role by which the immune system can limit 
or stimulate cancer growth is called cancer immunoediting [116]. The concept of immunoediting 
consists of three sequential phases: elimination, equilibrium and escape. In the elimination phase, 
cancer cells are destroyed before they become clinically apparent. If a cancer cell remains 
unrecognized and survives the elimination phase it may reach the equilibrium phase, where further 
outgrowth is prevented by several adaptive immunity mechanisms. Constant immune selection 
pressure placed on genetically unstable cancer cells may induce their escape from the immune 
system and cause clinically apparent disease [117]. The understanding of cancer immune evasion 
provided new ideas for the development of cancer therapeutics. The cytotoxic T-lymphocyte 
associated immune checkpoint inhibitors CTLA4 and PD-1/PD-L1 have been identified as the most 
relevant targets [118].  CTLA-4 is expressed exclusively on T cells and functions as a co-receptor 
for antigen presenting cells (APCs). Unlike the other T cell co-receptor CD28, CTLA-4 does not 
induce an anti-tumorigenic response [119]. The CTLA-4-targeting antibody ipilimumab improves 
survival of metastatic melanoma patients and has been approved by the US Food and Drug 
Administration (FDA) for this indication [120].  PD-1 is another costimulatory molecule expressed 
on the T cell surface that interacts with PD-L1 on APCs. Similar to CTLA-4, PD-1 binding prevents 
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T cell proliferation and secretion of anti-tumorigenic factors. Inhibition of PD-1 (e.g. with 
nivolumab) or PD-L1 (e.g. with pembrolizumab) improved the survival of cancer patients in clinical 
trials [121, 122]. Another class of immunotherapeutic agents are chimeric antigen receptor (CAR) 
T cells. In a procedure termed adoptive T cell therapy, T cells are isolated from cancer patients and 
are genetically modified with antigen-binding domains recognizing tumor antigens (e.g. CD19). 
The engineered CAR T cells are then reinfused into the patient where they can target tumor cells 
and activate anti-tumorigenic T cell responses [123, 124]. The FDA approved the first CAR T cell 
therapy (Kymriah) for the treatment of acute lymphoblastic leukemia. 
1.3.5 Radiotherapy 
Radiotherapy is the treatment of cancer patients by ionizing radiation (IR), which induces DNA 
double strand breaks that result in growth arrest and cell death. IR can either directly ionize and 
thereby damage DNA molecules or indirectly induce the production of free radicals from water 
and oxygen molecules within the tumor. For X-rays, approximately 60% of the cellular damage is 
triggered by free radicals that attack DNA molecules [125, 126]. IR does not discriminate between 
healthy and cancerous cells, which emphasizes the importance of accurate treatment planning 
and delivery. Owing to tremendous progress in the development of linear accelerators, it is now 
feasible to use imaging modalities and planning software to precisely deliver conformal high doses 
of IR to the tumor without overly co-irradiating the healthy surrounding tissue [127]. Radiation 
can be delivered either by linear accelerators (external beam radiotherapy) or by decaying 
radionuclides (brachytherapy). Based on the tumor entity and the hospital equipment, external 
beam radiotherapy can be applied by different physical moieties including photons, protons, 
electrons or carbon ions [128]. Typically, radiotherapy is combined with chemotherapy, 
immunotherapy or surgery. Radiotherapy is not only used for curative intent, but also to palliate 
advanced cancer patients and improve their quality of life [129].  
1.3.5.1 The 5 R’s 
In order to exploit the full potential of radiotherapy it is important to understand how radiation 
influences the biology and microenvironment of cancer cells and to apply these insights in 
translational studies [130]. Based on this notion, Steel et al. suggested the 5Rs that influence the 
outcome of radiotherapy and how their optimization may improve tumor control and reduce 
normal-tissue toxicity [131]. In the following lines, I will briefly describe the 5Rs, which will be 
discussed in more detail in section 1.4 Treatment resistance: 
Repair is induced by the DNA damage response machinery after radiation-induced double strand 
breaks in the DNA.  
Repopulation is caused by the enhanced proliferation rate of surviving cells that continue to grow 
and replace the cells killed by IR. 
Reassortment or Redistribution exploits the differential radiation sensitivity of cancer cells 
depending on the cell cycle phase. 
Reoxygenation of the TME after a dose fraction enhances the radiosensitivity of the following dose 
fractions. 
Radiosensitivity of cancer cells depends primarily on their proliferative rate, i.e. rapidly dividing 
cells are more radiosensitive than slowly proliferating cells. 
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1.3.5.2 Brachytherapy 
Brachytherapy is a treatment for cancer patients in which radionuclides are placed in close 
proximity to the lesion that should be irradiated. As such, it can be described as an invasive 
radiotherapy approach. Brachytherapy is used either as a single treatment or in combination with 
surgery or external beam radiotherapy. Moreover, it is used as a salvage therapy for local 
recurrence. Gynaecological tumors are the most common application for brachytherapy [132]. 
Other tumor entities include prostate, breast, eye, oesophagus and head & neck [133]. Typical 
radionuclides used in brachytherapy are 60Co, 192Ir and 125I [134]. 
1.3.5.3 Radiation physics and LINAC technology 
A linear accelerator (LINAC) generates X-rays by accelerating electrons and striking them on a high 
atomic number target (e.g. tungsten). When the electrons strike the target, electromagnetic 
radiation in form of photons are generated by an effect termed “Bremsstrahlung”. A contoured 
flattening filter subsequently shapes the photons (X-rays) to a uniform energy of typically 4 MeV 
to 10 MeV. The patient lies on a couch that can rotate and move in all three translational 
directions, while the LINAC gantry can rotate 360° around the patient and deliver the X-rays 
statically or dynamically. 
Photons are uncharged packets of energy that travel at the speed of light and exert forces to 
atoms in the human body. There are three main interactions that can occur. In photoelectric 
interactions, the photon collides with an electron that is repelled, leaving behind an ionized atom. 
Unlike in photoelectric interactions, where the entire kinetic photon energy is transferred to the 
escaping electron, in Compton interactions only a fraction of the kinetic photon energy is 
transferred to the escaping electrons while the initial photons are scattered and continue to travel 
with a lower kinetic energy. The third interaction is pair production, where photons interact with 
the atomic nucleus and create an electron and a positron. Compton interactions are the most 
important interactions of therapeutic photon beams. Once an atom has been ionized, some of 
the chemical bonds within the molecule will be disrupted leading to irreversible biological damage. 
The radiation dose is a measure of the amount of energy deposited at a point of interest and 
expressed in units of Gray (Gy), where 1 Gy = 1 J/kg [135].  
1.3.5.4 Fractionation and treatment scheduling 
The 5R’s are the best approach to describe the rationale of fractionated radiotherapy. One goal is 
to increase the damage to the tumor by reoxygenation of hypoxic cells and redistribution of cells 
along the cell cycle. At the same time, healthy tissue is spared by repair of sublethal damage and 
repopulation from surviving cells. The main variables influencing the design of  a fractionated 
treatment schedule are overall dose, number of fractions, dose per fraction and the time interval 
between fractions [136]. A conventional treatment schedule consists of 30 fractions with 2 Gy. 
Altered fractionation schedules have shown to be beneficial for cancer patients. One example is 
the improved survival in patients with head & neck cancer that were treated with 
hyperfractionated radiotherapy where IR-fractions are given more than once daily [137]. 
The other extreme is hypofractionated radiotherapy that delivers high doses of IR in a limited 
number of fractions. Hypofractionated radiotherapy, also termed as stereotactic body 
radiotherapy (SBRT) has emerged over the past decades due to remarkable technical progress. 
Numerous clinical investigations have demonstrated improved efficacy of SBRT as compared to 
conventional radiotherapy in cancer patients [138]. The underlying radiobiological mechanisms 
cannot be explained with the 5R’s of radiotherapy, therefore it is assumed that mechanisms other 
than direct cell killing of cancer cells through DNA DSBs are responsible for the improved efficacy 
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of SBRT. Secondary cell death by damaging the tumor vasculature and inducing an anti-tumor 
immune response are hypothesized as the main reasons for the success of SBRT. It was shown 
that IR-fractions above 10 Gy cause endothelial cell death and vascular disruption resulting in 
ischemic cancer cell death within a few days after irradiation. Vascular disruption and extensive 
cancer cell death further increase the release of tumor-associated antigens, thereby triggering an 
anti-tumorigenic immune response [139]. 
Sporadic clinical case reports have described a remission of non-irradiated cancer lesions after 
radiotherapy of primary tumors. This phenomenon was described as the “abscopal effect” and is 
associated with immunogenic responses after high-dose radiotherapy. The release of tumor 
antigens from the primary tumor improves antigen presentation to cytotoxic T cells, which in turn 
are activated and kill cancer cells at distant sites [140, 141]. 
1.3.5.5 Small animal radiotherapy 
Basic and applied research in the field of radiobiology helped to reveal the biological relation of 
ionizing radiation and cytotoxicity. Many lessons learned in preclinical trials were successfully 
translated into treatment options for cancer patients. However, the physical and technical aspects 
in preclinical research were historically always a few steps behind the corresponding developments 
in the clinical field. In contrast, innovations in clinical radiotherapy are primarily attributed to 
technological progress rather than a more comprehensive understanding of the underlying 
radiobiological mechanisms. 
With the development of small animal radiotherapy platforms, preclinical researchers aim to 
bridge the technological gap in radiation oncology. Cone beam CT (CBCT) based treatment 
planning with Monte Carlo dose calculation, followed by static or dynamic irradiation with 
millimeter-sized collimators enable to precisely deliver high conformal doses of IR to very small 
structures in animal models. Further development in the small animal radiotherapy field is leading 
towards the integration of functional imaging modalities like PET. As such, preclinical 
radiobiological studies can be performed in high accordance to clinical practice and investigate 
previously not applicable aspects including dose painting or spatiotemporal fractionation [142].  
1.3.6 Combined treatment modalities 
As previously mentioned, most cancer patients are treated with a combination of different 
treatment options in order to improve therapeutic success. Surgical tumor resections often go 
along with neoadjuvant chemo- or radiotherapy in order to reduce the extents of the tumor and 
permit surgery in previously inoperable disease. Likewise, adjuvant radiotherapy kills 
macroscopically invisible tumor cells remaining along the surgery margin and thereby further 
improves tumor control [109]. Other combined treatment modalities are often prescribed to 
prevent treatment resistance or to modulate cancer cells and their TME in a manner that enables 
synergistic therapy effects. The underlying mechanisms and rationales for combined treatment 
will be discussed in the following sections.  
1.4 Treatment resistance 
Treatment resistance is one of the major factors contributing to disease progression leading to 
treatment failure. The high adaptability of tumors can induce treatment resistance by distinct 
mechanisms. The genomic landscape of a tumor is highly heterogeneous among patients suffering 
from the same type of cancer, rendering targeted therapy ineffective in some cases. This is further 
complicated by intra-patient heterogeneity. Distinct mutational profiles within a tumor result in 
unequal therapeutic response to any anti-proliferative treatment options, which increases the 
probability that a subpopulation of cancer cells does not respond to a given cancer therapy [143]. 
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Functional genomic techniques are then employed to identify novel genes and signalling networks 
involved in treatment resistance [144]. 
Treatment resistance can be categorized into acquired resistance and intrinsic resistance. Intrinsic 
or innate resistance is the pre-existence of cancer cell properties that prevent the effectiveness of 
a certain treatment, e.g. by compensatory signalling pathways. Acquired resistance on the other 
hand develops over the course of the treatment, e.g. by mutational changes in a signalling 
network. Acquisition of treatment resistance is not exclusively driven by mutational changes on 
the cellular level but to a considerable extent also by alterations in the TME. Furthermore, it is 
important to understand the conceptual differences of chemoresistance and radioresistance. 
These key aspects will be discussed in the following sections. 
1.4.1 Chemoresistance 
Chemoresistance is a result of intrinsic or acquired resistance of cancer cells to chemotherapeutic 
or targeted agents. The list of causes for chemoresistance includes alterations of drug uptake, 
efflux and metabolization as well as alterations and decreased expression of drug targets, 
increased repair capacity and limited perfusion [145]. Specific DNA-mutations in cancer cells can 
lead to pseudo-resistance, whereupon molecularly targeted drugs become ineffective. A 
prominent example is the activation of alternative signalling pathways (e.g. c-Met) upon treatment 
with EGFR-tyrosine kinase inhibitors (TKIs) (e.g. erlotinib or gefitinib) [146]. A large number of 
patients acquire resistance to functionally and structurally unrelated drugs, a phenomenon termed 
as multidrug resistance (MDR). ATP-binding cassette (ABC) efflux transporters including P-
glycoprotein (P-gp) play an important role in MDR. These transmembrane proteins actively pump 
drugs out of the cell and thereby reduce intracellular drug concentrations [147]. Overexpression 
of P-gp is associated with drug resistance and has been reported in numerous tumor entities [148]. 
Drug-metabolizing enzymes of the cytochrome P450 (CYP) family mediate another important 
mechanism for chemoresistance. These enzymes are primarily expressed in the liver and 
metabolize drugs by the addition of a hydroxyl moiety that renders the xenobiotic compound 
more hydrophilic, which improves its secretion and thereby reduces intracellular drug 
concentrations. Approximately 70-80% of all drugs in clinical use are metabolized by CYPs [149]. 
1.4.2 Radioresistance 
The resistance of cancer cells to radiotherapy is determined by intrinsic cellular factors and by the 
surrounding TME. Adaptive changes of intracellular signalling pathways, primarily involved in DNA 
repair and replication, cell cycle arrest and apoptosis are some of the intrinsic factors leading to 
radioresistance. 
The most extensively involved pathways are the p53, phosphatidylinositol-3-kinases (PI3K) and 
epidermal growth factor receptor (EGFR) signalling cascades. IR has been shown to induce 
autophosphorylation of EGFR intracellular domains resulting in the activation of the PI3K/AKT 
signalling cascade. Hyperactivation of PI3K/AKT signalling results in enhanced proliferative activity 
and inhibition of apoptosis [150, 151]. Based on these features, EGFR overexpression is associated 
with poor prognosis, especially in glioblastoma and head & neck cancer patients [152, 153]. 
Another key regulator of intrinsic radioresistance is the tumor suppressor p53 that is strongly 
involved in the DNA damage response induced by IR [154]. 
1.4.2.1 Cell cycle control and DNA damage 
IR leads to the formation of DNA DSBs as previously described. The irradiated cells continue to 
grow until they arrive at the next cell cycle checkpoint, where different mechanisms assess 
whether the cell is fit for division or whether the DNA is damaged and needs to be repaired. The 
24
cells pass the checkpoint in case of successful DNA repair. If the induced damage cannot be 
repaired, the cell will undergo apoptosis. If a cancer cell evades the apoptotic process it will likely 
continue to proliferate and eventually develop new mutations [155]. Mammalian cells have two 
cell cycle checkpoints that are involved in DNA damage repair induction. The G1/S checkpoint is 
regulated by Cdk4/6 kinases and Cyclin D in a p53-dependent manner and commonly defective 
in cancer cells due to mutations in p53 or Cyclin D [156]. On the other hand, the G2/M checkpoint 
is primarily regulated via p53-independent mechanisms [157, 158]. Consequently, abrogation of 
the G2/M checkpoint sensitizes cancer cells to radiotherapy [159].  
The key regulators of the DNA damage repair response are ataxia telangiectasia and Rad3-related 
protein (ATR) and ataxia telangiectasia mutated (ATM). In presence of DNA DSBs  ATR and ATM 
are activated and in turn phosphorylate downstream targets including Chk1/Chk2, BRCA1 and 
p53, which eventually leads to cell cycle arrest [160]. During cell cycle arrest, IR-induced DNA DSBs 
can be repaired by two independent repair pathways termed homologous recombination (HR) and 
nonhomologous endjoining (NHEJ). In HR, the correct sequence is derived from an intact DNA 
strand, whereas in NHEJ damaged bases are digested, repolymerized and ligated [155]. Repair of 
DNA DSBs by HR is more precise than by NHEJ but limited to the S and G2 phases of the cell cycle 
[161]. 
1.4.2.2 TME-driven radioresistance 
Historically, radiation biologists have primarily paid attention to intrinsic radioresistance. Basic 
research and clinical evidence over the past century yet revealed that radioresistance driven by the 
tumor microenvironment also negatively influences the outcome of radiotherapy. 
It was shown that upon irradiation CAFs release TGF-β, which mediates ECM remodelling in 
irradiated tissues and results in tumor progression, fibrosis and metastases [162, 163]. 
Furthermore, it leads to the activation of DNA damage-associated factors including p53 and to 
enhanced expression of p21, which triggers cell cycle arrest [164, 165]. Bone marrow derived cells 
(BMDCs) mainly consisting of tumor-associated macrophages (TAMs), mononuclear cells and 
myeloid derived immune suppressive cells are recruited to the TME following irradiation. They are 
involved in the restoration of the IR-induced vascular damage through vasculogenesis and thereby 
drive tumor regrowth and metastatic spread [166, 167]. Cancer stem cells (CSCs) are another 
factor contributing to radioresistance. Owing to their enhanced DNA-repair capacity, self-renewal 
potential and defense mechanisms against reactive oxygen species (ROS), they are intrinsically 
more resistant to IR. By resisting IR-induced cell death, CSCs further contribute to adaptive 
radioresistance via their selective repopulation [168]. 
Tumor hypoxia is one of the major limiting factors for successful radiotherapy. X-ray mediated 
ionization results in the formation of radicals within the DNA structure (DNA·). In the presence of 
molecular oxygen DNA radicals can be irreversibly fixed with ROS, including hydroxyl (HO·), peroxyl 
(ROO·) and superoxide (O·-2) radicals [169]. ROS-mediated radical fixation is followed by DNA DSBs 
and cell death. Under hypoxic conditions, ROS are not sufficiently aberrant to fix IR-induced DNA 
radicals and are outperformed by thiol-containing compounds that reduce the DNA-radical to its 
native form. Consequently, IR-induced DNA damage and cell death are reduced in hypoxic regions 
of the tumor. This phenomenon was termed “Sauerstoffeffekt” and it can be roughly estimated 
that hypoxic cells are up to three times more radioresistant than their normoxic counterparts [170]. 
Numerous clinical trials have demonstrated that patients with a lower hypoxic tumor fraction have 
an improved overall survival after radiotherapy [95, 171]. 
Besides the physicochemical aspects for hypoxia-mediated radioresistance described above, the 
concurrent activation of HIF-signalling also gives rise to radioresistance on a more biological level. 
For example, HIF-1 signalling leads to the activation of MDM2, which negatively regulates p53 
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and thereby renders hypoxic cells resistant to apoptosis and promotes cell survival after 
radiotherapy [172]. Moreover, HIF-1 can negatively affect the radiosensitivity of tumors by altering 
their cellular metabolism. In a process named the Warburg effect, cancer cells switch their energy 
metabolism in favour of aerobic glycolysis over oxidative phosphorylation. It was shown that the 
Warburg effect negatively influences the outcome of radiotherapy by enhancing the DNA damage 
repair of cancer cells [173, 174]. 
The vicious cycle of hypoxia and angiogenesis is further promoted by radiotherapy. Endothelial 
cells within the TME are relatively radiosensitive due to their rapid proliferation rates [175]. 
Especially high dose fractions of IR have been shown to induce endothelial cell apoptosis, resulting 
in post-radiation hypoxia that in turn may lead to metastatic spread [176]. 
 
 
Figure 6 a) Ionizing radiation produces DNA radicals that can be fixed by molecular oxygen, thereby 
generating irreversible DNA double strand breaks followed by cell death. Under hypoxic conditions, 
glutathione-like molecules reduce DNA radicals to its native form, thus preventing cell death. b) In response 
to low intracellular oxygen concentrations, cancer cells release HIF-1α. At the same time, RT-mediated tumor 
reoxygenation leads to increased ROS levels further stabilizing HIF-1α, which induces the expression of target 
genes inclusing VEGF and CXCL12. c & d) Increased influx of BMDCs together with VEGF aid tumor 
recurrence after radiotherapy [176]. 
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1.5 Combined treatment modalities to overcome radioresistance 
A multitude of intrinsic and adaptive factors contributes to the radioresistance of cancer cells. 
Targeted therapies to overcome some of these restrictive factors have been developed over the 
past decades. Current clinical radiotherapy protocols typically involve at least one additional 
treatment regimen to improve the success of radiotherapy. Based on their mode of action, 
combined treatment agents are either administered before (neoadjuvant), during (concomitant) 
or after (adjuvant) radiotherapy. In the following paragraphs, some of the most relevant 
combination treatment strategies to overcome radioresistance will be discussed. 
1.5.1 Targeting intracellular signalling pathways 
Attempts to target increased EGFR expression and the corresponding activation of the PI3K/AKT 
pathway have led to the evaluation and implementation of different pharmaceutical agents. The 
most important development was the EGFR-targeting antibody Cetuximab, which in combination 
with radiotherapy was used for the treatment of HNSCC where it successfully improved patient 
overall survival [177, 178]. However, clinical evidence showed that cancer cells became resistant 
to EGFR inhibitors due to activation of the MET pathway as a compensatory mechanisms [179]. 
To overcome EGFR-blockade resistance, drugs targeting the downstream PI3K/AKT pathway are 
being investigated and show preliminary anti-tumor activity and acceptable safety profiles in early 
clinical trials [180]. 
1.5.2 Targeting DNA damage and cell cycle control pathways 
Another strategy to improve the efficacy of radiotherapy is to target proteins involved in the DNA 
damage response. One example is the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib, 
which is used for the treatment of tumors with mutations in BRCA1 or BRCA2 and corresponding 
defects in HRR [181]. On the preclinical level, PARP inhibition in combination with radiotherapy 
was shown to increase the incidence of collapsed replication forks resulting in persistent DNA 
DSBs [182]. Olaparib is approved as single treatment for BRCA-mutated breast and ovarian cancer 
but latest preclinical results and hypotheses are pointing towards a radiosensitizing effect, 
especially in combination with proton radiotherapy [183, 184].  
Microtubule-stabilizing agents (MSA) induce cells to arrest at the G2/M checkpoint, which was 
identified as the most radiosensitive phase of the cell cycle [185]. Combined treatment of IR and 
MSAs is therefore a promising approach to overcome radioresistance. Our preclinical research with 
novel MSAs has led to clinical trials that investigate the combined effect of IR and MSAs [186]. 
1.5.3 Targeting the tumor vasculature 
VEGF overexpression in solid tumors drives the vicious cycle of angiogenesis and hypoxia, resulting 
in decreased radiosensitivity of the cancer cells. Phase III clinical trials investigating the combined 
treatment of radiotherapy and bevacizumab in glioblastoma patients failed to improve overall 
survival. However, there was a modest increase in progression-free survival and quality of life 
[187]. Early clinical trials with the newer-generation VEGF inhibitors sorafenib and sunitinib also 
failed to show increased overall survival and were accompanied with severe toxicity [188, 189]. 
Based on these findings and current understanding it can be concluded that the tumor vasculature 
is not an attractive target to increase the efficacy of radiotherapy. 
1.5.4 Targeting immune cells 
Immune checkpoint inhibitors have recently shown promising results in improving the overall 
survival of melanoma and lung cancer patients [120-122]. Since radiotherapy increases antigen 
27
presentation and immune cell infiltration in the tumor it is believed to be a potent sensitizer for 
immune checkpoint therapy. First clinical trials showed only modest improvements in overall 
patient survival after combined radioimmunotherapy with ipilimumab in prostate cancer [190]. 
Numerous clinical trials with distinct immune checkpoint inhibitors for various indications are 
currently ongoing [191, 192]. Immune checkpoint blockade is presently the most extensively 
studied combination approach in the field of radiotherapy. 
1.5.5 Targeting tumor hypoxia 
The key aim of my doctoral thesis has been to target tumor hypoxia in order to overcome 
radioresistance. Tumor hypoxia is an interesting target for radiosensitization, since all solid tumors 
irrespective of their site and genetic background develop hypoxic tumor regions. Hypoxia can be 
modulated on the biological level by targeting deregulated signalling molecules, such as HIF-1α 
and CAIX, or on the physiological level by specifically targeting or reoxygenating hypoxic cancer 
cells. 
The development of HIF-inhibitors interfering with HIF mRNA expression, protein synthesis, protein 
degradation, DNA binding or transcriptional activity were approved for treating cancer patients. 
Promising compounds like acriflavine or YC-1 failed to show therapeutic efficacy or were 
associated with treatment-induced toxicity [193]. 
Oxygen mimetic drugs belonging to the group of nitroimidazoles were investigated extensively. 
Clinical trials combining misonidazole with radiotherapy did not improve the outcome. Moreover, 
a substantial amount of patients developed peripheral neuropathy upon misonidazole treatment 
[194]. Although the next generation therapeutic nimorazole had fewer side effects, it only showed 
modest benefits in efficacy [195]. 
Hypoxia-activated prodrugs (HAPs) are compounds that get bioreductively activated in areas of 
low oxygen concentrations where they subsequently exert cytotoxic functions by DNA alkylation. 
Tirapazamine and evofosfamide as shown by our own laboratory and several others demonstrated 
a promising radiosensitizing potential in preclinical tumor animal models [196, 197]. A phase I 
clinical trial investigating the combined treatment modality of radiotherapy and evofosfamide was 
discontinued, since evofosfamide alone failed to improve overall patient survival in phase II & III 
clinical trials [198-200].  
An alternative to radiosensitization is to reoxygenate the hypoxic tumor fraction prior to 
irradiation. Since compounds that directly increase tumor oxygenation are rare, there have been 
attempts to indirectly increase the oxygen concentration within the tumor with the use of 
erythropoietin (EPO), a cytokine that is endogenously secreted by the kidneys in response to 
hypoxia. Clinical administration of recombinant EPO failed to improve the outcome of 
radiotherapy and the possibility of a detrimental effect could not be excluded [201]. ARCON 
treatment combines accelerated radiotherapy (multiple IR fractions per day) with inhalation of 
carbogen (98% O2 + 2% CO2) and the vasodilator nicotinamide to decrease tumor hypoxia. 
ARCON treatment in patients with laryngeal cancer improved the regional control in comparison 
to accelerated radiotherapy alone, but failed to significantly improve local control and overall 
survival [202]. 
As part of my doctoral thesis, we investigate the novel tumor reoxygenting agent myo-inositol 
trispyrophosphate (ITPP). It is actively taken up by red blood cells whereupon it triggers a decrease 
of the oxygen/hemoglobin binding affinity, resulting in enhanced oxygen release and 
reoxygenation of hypoxic tissues [203, 204]. Besides this rapidly induced physicochemical effect, 
ITPP further normalizes tumor hypoxia by downregulating pro-angiogenic factors like HIF-1α and 
VEGF leading to a long lasting normalization of the TME [41].  
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 Figure 7 Radioresistance can be reduced by targeting different compartments of the TME. a) Targeting of 
tumor hypoxia and vasculature aims to increase the oxygen delivery to cancer cells before or during 
irradiation. b) Increased immune-cell infiltration and tumor antigen presentation after radiotherapy can be 
achieved by targeting immune cells. c) Targeting of fibrosis aids in preventing ECM remodeling or TGF-β 
singalling associated with radioresistance and recurrence [176]. 
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2. Aims of the study 
Tumor hypoxia is associated with resistance to radiotherapy, an increased risk of tumor 
dissemination and poor clinical prognosis. Reactive oxygen species induced by ionizing radiation 
generate irreversible DNA double-strand breaks followed by chromosomal aberrations and cell 
death. This radiation-induced cytotoxic effect is less abundant under hypoxia and thus hypoxic 
cells are more resistant to radiotherapy.  
In this PhD project, we aim to modulate tumor hypoxia with pharmaceutical agents as part of 
combined treatment modalities with hypofractionated radiotherapy. The rationale is to develop 
novel combination therapies that aid to overcome hypoxia-mediated radioresistance of solid 
tumors. The ultimate goal is to apply the gained knowledge into treatment protocols for cancer 
patients undergoing radiotherapy. Our specific aims are: 
 
1. We investigate the combined treatment of the hypoxia-activated prodrug evofosfamide 
and radiotherapy in vitro. To reveal the underlying mechanism of differential response to 
evofosfamide treatment in different cell lines, proliferative activity, clonogenic cell survival 
and pattern of DNA damage upon combined treatment are examined. Furthermore, the 
involvement of drug-metabolizing enzymes for prodrug activation is studied across 
responding and non-responding cell lines. 
2. In the second project, we investigate the potential of the anti-hypoxia compound myo-
inositol trispyrophosphate (ITPP) to overcome radioresistance. The radiosensitizing effect 
is tested by tumor growth delay studies in vivo, using different tumor entities with varying 
tumor hypoxic fractions. The contribution of the immune system is determined by 
performing experiments in both, immunodeficient and immunocompetent mice. 
Additional functional endpoints including differential progression of the TME upon 
combined treatment are investigated by exhaustive immunohistochemical stainings. 
Kinetics of tumor reoxygenation by non-invasive hypoxia-imaging and characterization of 
treatment-induced DNA damage complete the extensive exploration. 
Finally, an orthotopic colorectal liver metastases model was developed and investigated to 
study multimodal treatments in a tumor model that is representing clinical radiotherapy in 
a more concise manner. 
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ABSTRACT
The promising treatment combination of ionizing radiation (IR) with a hypoxia-
activated prodrug (HAP) is based on biological cooperation. Here we investigated 
the hypoxia-activated prodrug evofosfamide in combination with different treatment 
regimens of IR against lung A549- and head&neck UT-SCC-14-derived tumor 
xenografts. DNA damage-related endpoints and clonogenic cell survival of A549 and 
UT-SCC-14 carcinoma cells were probed under normoxia and hypoxia.
Evofosfamide (TH-302) induced DNA-damage and a dose-dependent 
antiproliferative response in A549 cells on cellular pretreatment under hypoxia, and 
supra-additively reduced clonogenic survival in combination with IR. Concomitant 
treatment of A549-derived tumor xenografts with evofosfamide and fractionated 
irradiation induced the strongest treatment response in comparison to the 
corresponding neoadjuvant and adjuvant regimens. Adjuvant evofosfamide was more 
potent than concomitant and neoadjuvant evofosfamide when combined with a single 
high dose of IR. Hypoxic UT-SCC-14 cells and tumor xenografts thereof were resistant 
to evofosfamide alone and in combination with IR, most probably due to reduced 
P450 oxidoreductase expression, which might act as major predictive determinant 
of sensitivity to HAPs.
In conclusion, evofosfamide with IR is a potent combined treatment modality 
against hypoxic tumors. However, the efficacy and the therapeutic outcome of this 
combined treatment modality is, as indicated here in preclinical tumor models, 
dependent on scheduling parameters and tumor type, which is most probably related 
to the status of respective HAP-activating oxidoreductases. Further biomarker 
development is necessary for the launch of successful clinical trials.
INTRODUCTION
Radiotherapy, along with surgery and chemotherapy 
is one of the major treatment options for solid tumors. 
However, solid tumors are often radiation resistant due to 
tumor hypoxia, which thereby represents a major clinical 
challenge. Several strategies have been developped 
during the last decades to overcome the hurdle of tumor 
hypoxia for successful radiotherapy [1–4]. One of these 
concepts is based on biological cooperation, which refers 
to strategies that target distinct cell populations, or employ 
different mechanisms for cell killing. The combination 
of ionizing radiation (IR) with a Hypoxia-Activated 
Prodrug (HAP), targeting hypoxic tumor cells and thereby 
complementing the effect of IR in well-oxygenated cells, 
nicely represents the concept of biological cooperation [5]. 
Originally, nitrobenzenes, followed by the nitroimidazoles 
(misonidazole, etanidazole, pimonidazole) [6], were 
proposed to act as oxygen mimetic agents and to generate 
together with short-lived IR-induced free DNA radicals 
cytotoxic DNA strand breaks [7, 8]. Unfortunately, and 
despite the clarity of the concept, severe toxicities of these 
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early generation compounds have contributed that these 
hypoxic radiosensitizers did not find their recognition in 
the clinical routine. Nevertheless these findings paved the 
way for the generation of hypoxia-selective bioreductive 
prodrugs, which are activated by enzymatic reduction in 
hypoxic tissues [9].
This risk of severe side-effects is reduced with 
HAPs that are less toxic and especially with compounds 
that are only activated under severe hypoxia. At the same 
time such prodrugs should release a diffusible, active 
cytotoxic agent, not only to kill the most hypoxic tumor 
cells, but also to induce a bystander effect thereby killing 
tumor cells of intermediate levels of tumor hypoxia. The 
2-nitroimidazole-conjugated bromo-isophosphoramide 
mustard (Br-IPM) evofosfamide (TH-302) represents a 
prototype of such a novel generation HAP. Evofosfamide 
is currently the most advanced compound in clinical trials 
of the new generation of bioreductive cytotoxins [10–12].
The development of linear accelerator technology 
for the precise delivery of radiotherapy has nowadays 
reached a level of dose conformity to the tumor that allows 
the application of high dose fractions (even > 10 Gy) to 
small tumors with very steep dose gradients. Fractionated 
application of daily doses of IR exploits reoxygenation of 
hypoxic tumor regions in between fractions and thereby 
overcomes the hypoxic challenge as part of an iterative 
process. On the other hand single high doses of IR or a 
hypofractionated treatment regimen requires other means 
to improve its efficacy and to control a hypoxic tumor e.g. 
by the combined treatment modality with a HAP [13, 14].
Here we investigated the potency of evofosfamide in 
combination with fractionated and single high-dose of IR 
and tested these regimens in three settings (neoadjuvant, 
concomitant and adjuvant) routinely applied in clinical 
practice. Furthermore, the influence of treatment 
conditions linked to the individual geno- and phenotype 
of the tumor, including the status of the HAP-activating 
oxidoreductases, DNA-damage repair machineries and the 
hypoxic burden, was analyzed.
RESULTS
Evofosfamide in combination with IR in vivo
The combined treatment modality of IR with an 
HAP is based on biological cooperation. However, the 
most effective scheduling of the two modalities is not 
predictable. We therefore probed three different treatment 
schedules (neoadjuvant, concomitant and adjuvant) of a 
minimally fractionated irradiation regimen (3x2 Gy on 3 
consecutive days) and evofosfamide (50 mg/kg, Q3Dx5) 
in a lung adenocarcinoma (A549) and a head&neck 
squamous cell carcinoma (UT-SCC-14) tumor xenograft 
model. The dosage and schedule of evofosfamide was 
defined based on previous preclinical reports when 
used as part of a combined treatment modality [15] and 
closely mimic the settings used in clinical practice. 2 
Gy per fraction of IR corresponds to the dose/fraction 
used as part of a clinical fractionated radiotherapy 
treatment regimen. Both tumor models were previously 
characterized to develop tumors with an intermediate 
hypoxic tumor fraction [16, 17]. Tumor hypoxia was 
also confirmed by pimonidazole staining (Supplementary 
Figure 1). Treatment was initiated when tumors reached a 
volume of 300 mm3 (+/- 10%). Treatment of A549-derived 
tumor xenografts with evofosfamide in combination with 
fractionated irradiation resulted in a strongly enhanced 
treatment response when compared to treatment with 
evofosfamide and irradiation alone (Figure 1A). The 
concomitant schedule induced the strongest tumor 
growth delay (P<0.05 for evofosfamide plus IR versus 
each monotherapy), however, no statistically significant 
differences in between the three combined treatment 
regimens could be determined. Interestingly, evofosfamide 
alone did not reduce tumor growth of HNSCC UT-SCC-14 
xenografts and did not enhance the growth inhibitory 
effect of fractionated irradiation as part of a combined 
treatment modality (Figure 1B). These results suggest that 
the response to evofosfamide and IR is highly dependent 
on the tumor type.
Due to the differential treatment response in the two 
tumor models in vivo, the effect of evofosfamide was also 
determined in vitro with defined hypoxic conditions (0.2% 
O2). Interestingly, A549 cells were also more sensitive than 
UT-SCC-14 to increasing concentrations of evofosfamide 
(Supplementary Figure 2). The cytochrome P450 
oxidoreductase (POR) has previously been identified as 
major determinant for the sensitivity of hypoxia-activated 
prodrugs [18, 19]. Therefore, the expression level of POR 
was determined on the cellular and tumor level by western 
blotting and immunohistochemistry, respectively. The 
POR expression level was strongly reduced in UT-SCC-14 
cells and UT-SCC-14-derived tumors in comparison 
to A549 cells and tumors derived thereof (Figure 2A, 
2B). This is most probably the cause for evofosfamide-
resistance against the head&neck tumor model used in 
this study. Furthermore, transient downregulation of 
POR in A549 cells with POR-directed siRNA resulted in 
reduced sensitivity to evofosfamide in these cells relative 
to control siLUC-transfected A549 cells (Supplementary 
Figure 3), reinforcing the role of POR for evofosfamide 
sensitivity. Despite several attempts, we could not perform 
the opposite experimental approach to overexpress POR 
in UTSCC-14 cells. These cells did always undergo cell 
death upon genetic manipulation alone.
To further analyze the differential treatment 
response in between A549 and UT-SCC-14-derived 
tumors, comprehensive analysis of hypoxia-related 
secreted factors was performed by Bio-plex analysis. 
Unfortunately, the levels of serum secreted factors in 
mice carrying tumor xenografts were below detection 
limits. Therefore, in vitro analysis of conditioned media 
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derived from A549 and UT-SCC-14 cells was performed. 
The basal secretory levels of most factors analyzed were 
different in between the two cell lines (e.g. VEGF, IL-
6, Osteopontin, sEGFR, TNFα) and did not change in 
response to evofosfamide treatment (Supplementary 
Figure 4). Interestingly, placental growth factor (PlGF) 
was strongly increased in A549 but not in UT-SCC-14 
cells in response to evofosfamide, suggesting that an 
increase of PlGF might be used as an early response 
biomarker (Figure 2C).
Next, the potency of evofosfamide was investigated 
in the evofosfamide-sensitive A549-derived tumor model 
as part of a combined treatment modality (neoadjuvant, 
concomitant, adjuvant) with a single high dose of IR (10 
Gy). The adjuvant combined treatment modality was 
most effective and induced a strong tumor growth delay 
in comparison to evofosfamide and IR alone (P<0.05 
for evofosfamide plus IR versus each monotherapy). 
Concomitant treatment with IR and evofosfamide only 
induced a partial additive tumor growth delay. On the other 
hand tumors almost doubled in size during the time period 
of neoadjuvant treatment with evofosfamide. Thereby 
tumors were irradiated at an increased tumor volume with 
a single high dose of IR, resulting in a reduced overall 
treatment response to the neoadjuvant combined treatment 
regimen (Figure 3A, 3B).
Enhanced radiosensitivity upon evofosfamide 
treatment in vitro
In vitro experiments with A549 cells demonstrated 
a dose- and hypoxia incubation time-dependent 
antiproliferative effect of evofosfamide (Figure 4A). To 
determine cancer cell clonogenicity, A549 cells were 
incubated with evofosfamide (0.5 μM) for 4 hours under 
hypoxia (0.2% O2) and normoxia, respectively, followed 
by irradiation under reoxygenated conditions. Combined 
treatment of A549 cells with evofosfamide and increasing 
doses of IR resulted in a strong, supra-additive reduction 
of clonogenicity when cells were preincubated with 
Figure 1: Treatment response to evofosfamide and fractionated irradiation in vivo. Tumor growth delay of A549-derived 
(A) and UT-SCC-14-derived (B) tumor xenografts in response to different treatment schedules of the combined treatment modality with 
evofosfamide (50 mg/kg, Q3Dx5) and fractionated irradiation (3x2 Gy). Control mice were treated i.p. with saline. Neoadjuvant (left 
panel), concomitant (middle panel), and adjuvant (right panel) regimens are shown. Neoadjuvant (left panel), with evofosfamide given on 
days 1-12 followed by fractionated irradiation; concomitant (middle panel), with evofosfamide given on days 1-12 and IR on days 5-7; 
adjuvant (right panel), IR given on days 0-2 (fractionated) followed by treatment with evofosfamide. 7-8 mice per treatment groups were 
used. Error bars represent SEM. (C) Kaplan-Meier curves for A549-derived tumors reaching 600mm3 tumor volume.
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Figure 2: Differential POR- and PLGF-levels in A549 and UT-SCC-14 tumors. (A) Protein levels of cytochrome P450 
oxidoreductase (POR) in A549 and UT-SCC-14 cells incubated under normoxia (21% O2) and hypoxia (0.2% O2, 24 hours) as determined 
by western blotting. (B) Staining of A549 (left) and UT-SCC-14 (right)-derived tumor xenografts sections with anti–POR antibodies. 
(C) Levels of secreted PLGF in A549 and UT-SCC-14 conditioned medium in normoxia (21% O2) and hypoxia (0.2% O2, 24 hours) as 
determined using Bio-plex assay. Data are shown as fold induction over non-treated normoxic samples in three independent experiments, 
error bars represent SEM.
Figure 3: Treatment response to evofosfamide and single high-dose irradiation in vivo. Tumor growth delay of A549-derived 
xenografts in immunocompromised mice in response to combined treatment with evofosfamide (50 mg/kg, Q3Dx5) and single high-dose 
IR (1x10 Gy). Control mice were treated i.p. with saline. (A) Neoadjuvant (left panel), concomitant (middle panel), and adjuvant (right 
panel) regimens are shown. Neoadjuvant (left panel), with evofosfamide given on days 1-12 followed by irradiation; concomitant (middle 
panel), with evofosfamide given on days 1-12 and IR on day 6; adjuvant (right panel), IR given on day 0 followed by treatment with 
evofosfamide. 7-14 mice per treatment groups were used. Error bars represent SEM. (B) Kaplan-Meier curves for tumors reaching 600mm3 
tumor volume.
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evofosfamide under hypoxic conditions in comparison to 
preincubation under normoxic conditions (DEF0.1=1.44+/-
0.07 vs DEF0.1 of 1.16 +/- 0.07 respectively, and 
DEF0.37=1.72+/-0.12 vs DEF0.37=1.23+/-0.24, respectively) 
(Figure 4B).
The adjuvant schedule of evofosfamide in 
combination with IR resulted in a strong tumor growth 
delay in vivo. Therefore a reversed schedule with 
irradiation of cells (2 Gy) followed by incubation with 
evofosfamide (0.5 μM for 4 hours, 0.2% O2) was also 
probed in vitro. Combined treatment also resulted 
in a statistically significant increase of cell killing in 
comparison to cellular treatment with evofosfamide and 
IR alone (Figure 4C).
Induction of DNA damage and senescence in 
response to evofosfamide
Activation of the prodrug evofosfamide results in 
the potent DNA-alkylating agent bromo isophosphoramide 
mustard and induces a strong DNA damage response. 
Residual DNA damage was determined by γH2AX foci 
Figure 4: Treatment response to evofosfamide and irradiation in vitro. (A) Proliferation of A549 lung adenocarcinoma cells 
in response to increasing doses of evofosfamide. Cells were pre-incubated in hypoxia (0.2% O2) for 23 hours, followed by treatment with 
increasing concentrations of evofosfamide under hypoxic conditions for 1 hour (left panel). Proliferation of A549 cells pre-incubated for 
23, 18 and 2h in hypoxia (0.2% O2), followed by treatment with evofosfamide (0.5 μM) under hypoxia for 1, 6 and 22 hours, respectively 
(right panel). The proliferative activity of reoxygenated cells was monitored over 72 hours. (B) To determine time-dependent effects of 
evofosfamide, cells were incubated for 23, 18 and 2h in hypoxia (0.2% O2), followed by treatment with evofosfamide (0.5 μM) for 1, 6 
and 22 hours, respectively. The proliferative activity of reoxygenated cells was monitored over 72 hours. (B) Clonogenic cell survival 
assay of A549 cells treated with 0.5 μM evofosfamide under normoxic (21% O2) and hypoxic (0.2% O2) conditions for 4 hours. Following 
reoxygenation, cells were irradiated with increasing doses of IR. (C) Clonogenic survival assay of lung carcinoma A549 cells irradiated 
with 2 Gy and treated thereafter with evofosfamide (0.5 μM) under normoxic (21% O2) and hypoxic (0.2% O2) conditions for 4 hours 
(adjuvant setting); Error bars represent SEM.
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detection in A549 cells on treatment with evofosfamide 
and IR alone and in combination. As expected, a high level 
of residual DNA-damage was present at the 24 hour time 
point on initial cellular incubation with evofosfamide for 
4 hours under hypoxic but not under normoxic condition. 
Interestingly, combined treatment with irradiation (2 Gy) 
only resulted in a minimal but statistically not significant 
additional increase of residual DNA damage (Figure 5A). 
Lack of additional residual γH2AX foci in cells treated 
with both modalities does not correspond with the supra-
additive cell killing by the combined treatment modality 
in vitro (see above Figure 4B, 4C). Similar results were 
obtained when DNA damage was probed on the level of 
residual 53BP1-foci (Supplementary Figure 5).
Senescence is a well-known mode of cell death 
induced upon treatment with alkylating agents [20]. A 
high percentage of β-galactosidase positive A549 cells was 
induced on treatment with evofosfamide under hypoxic 
conditions, which was further increased on combined 
treatment with IR (Figure 5B). These results demonstrate 
that evofosfamide alone induces a strong DNA damage 
response and senescence in lung carcinoma cells. The 
small increase in the number of senescent cells in response 
to evofosfamide in combination with IR corresponds 
in part with decreased clonogenicity of A549 cells in 
response to this combined treatment modality.
Increased cell killing by evofosfamide in BRCA2-
deficient ovarian carcinoma cells
Evofosfamide-induced DNA damage requires 
homologous recombination for efficient DNA repair as 
previously shown in non-tumorigenic chinese hamster 
ovary cells [19]. To further investigate evofosfamide 
in combination with IR in tumorigenic cell lines and 
with defined HR-deficiency, proliferative activity and 
clonogenicity was determined in the BRCA2-wildtype 
PEO4 and the otherwise genetically identical BRCA2-
deficient ovarian carcinoma cell line PEO1 [21]. As 
expected, BRCA2-deficient PEO1 cells were more 
sensitive to increasing concentrations of evofosfamide 
in comparison to BRCA2-wildtype PEO4 cells under 
hypoxic conditions (Figure 6A). Moreover, combined 
treatment with IR reduced clonogenic cell survival in 
Figure 5: DNA damage in response to evofosfamide and irradiation. (A) Residual γH2AX foci were analyzed in A549 cells 
treated for 4 hours with evofosfamide and irradiation with 2 Gy. Cells were analyzed 20 hours after irradiation at a magnification of 40x. (B) 
Induction of senescence (β-galactosidase staining) in response to the combined treatment in A549 cells. Cells were analyzed 72 hours after 
treatment at a magnification of 10x. At least 50 cells/condition were analyzed. Representative pictures are shown. Error bars represent SEM.
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PEO1 cells to a higher extent than in the BRCA2-wildtype 
counterpart cells (Figure 6B). The ratio of survival 
fractions in response to evofosfamide and evofosfamide 
in combination with IR was 25.5 and 17.9 for PEO1 and 
PEO4 cells, respectively. The ratio of survival fractions 
in response to IR and the combined treatment modality 
was 7.1 and 2.7 for PEO1 and PEO4, respectively. These 
results strongly indicate a superior appliance for this 
combined treatment modality in tumors with homologous 
recombination-deficiency.
DISCUSSION
Evofosfamide is one of the most promising 
hypoxia-targeting agents currently tested in several 
clinical trials. Here we have investigated the combined 
treatment modality of evofosfamide with IR in a lung 
and a head&neck carcinoma model with a specific 
focus on multiple treatment regimens and schedulings. 
IR is known to target primarily well-oxygenated 
cells, while hypoxic cells are radiation-resistant. 
Therefore, the combined treatment modality of IR with 
evofosfamide is based on the promising rationale named 
biological cooperativity [5]. Both tumor models stained 
positive and to similar extent for the hypoxia-marker 
pimonidazole, however head&neck tumor xenografts 
were completely resistant to evofosfamide alone and 
when combined with IR, independent of the treatment 
scheduling. Subsequent expression studies revealed 
strongly reduced cytochrome P450 oxidoreductase 
(POR) levels in this tumor model. On the other hand 
A549 cells and A549 -derived tumor xenografts stained 
POR-positive and were highly evofosfamide-sensitive 
in vitro and in vivo.
Recently the dual combined treatment modality of 
IR with evofosfamide was shown to enhance the effect of 
radiotherapy in a rhabdomyosarcoma R1 and in a H460-
derived non-small-cell lung cancer tumor model and as 
part of a trimodality therapy in sarcoma models with the 
anti-VEGF receptor-directed antibody DC101 [15, 22]. In 
both studies only single high doses of IR were applied and 
scheduling of evofosfamide with IR was not investigated.
We here tested three different treatment regimens 
(neoadjuvant, concomitant, adjuvant) in combination 
with fractionated and single high-dose IR in the lung 
adenocarcinoma tumor model. A more potent neoadjuvant 
and concomitant versus adjuvant scheduling of the 
combined treatment modality of evofosfamide with 
fractionated IR was identified, which might coincide with 
evofosfamide initially targeting the major tumor hypoxic 
burden followed by fractionated irradiation including 
partial reoxygenation of the remaining hypoxic areas.
On the other hand the more potent adjuvant 
scheduling of evofosfamide in combination with a single 
high dose of IR could be due to an (transient) increase 
of tumor hypoxia in response to single high doses of 
IR [23, 24]. Interestingly own experiments performed 
independently of this study also demonstrated an increase 
of tumor hypoxia over time in response to a single high 
dose of IR in this tumor model (Supplementary Figure 
6). Similar to former studies with evofosfamide we only 
considered tumor growth delay as an endpoint and the 
hypoxic situation might vary in between different tumors. 
As such these schedulings will have to be carefully 
translated to the clinical situation.
Several studies on the activation of HAPs previously 
demonstrated that cytochrome P450 oxidoreductase is 
indispensable for several HAPs [18, 19, 25]. However, its 
Figure 6: Treatment response of BRCA2-deficient (PEO1) and BRCA2-wild-type (PEO4) ovarian carcinoma cells to 
evofosfamide and irradiation. (A) Cells were pre-incubated in hypoxia (0.2% O2) for 20 hours, followed by treatment with increasing 
concentrations of evofosfamide for 4 hours. The proliferative activity of reoxygenated cells was monitored over 72 hours. (B) Clonogenic 
cell survival assay of BRCA2 deficient (PEO1) and wild-type (PEO4) cells in response to evofosfamide (0.5 μM) and irradiation with 4 
Gy. Cells were pre-incubated in hypoxia (0.2% O2) for 20 hours, followed by evofosfamide treatment under hypoxic conditions (4 hours), 
reoxygenation and irradiation with 4 Gy. Error bars represent SEM.
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relevance for the nitroimidazole mustard evofosfamide is 
less clear. Su et al. knocked-out POR in multiple tumor 
cell lines that resulted in resistance to several one-electron 
reductase substrates but not to evofosfamide, suggesting 
the existence of structure-dependent oxidoreductase 
redundancies [26]. On the other hand, Hunter et al. recently 
demonstrated reduced cytotoxicty of evofosfamide in 
head&neck carcinoma cells with shRNA-downregulated 
POR-expression [18]. More important, a heterogeneous 
POR expression status was retrospectively determined in 
head&neck squamous cell carcinoma patient samples, and 
suggests that POR might be a major predictive determinant 
for HAPs including evofosfamide [18]. Our own studies, 
which were performed on the cellular level and to our best 
knowledge for the first time also in vivo, strongly suggest 
that POR co-determines the potency of evofosfamide. As 
such we demonstrate minimal efficacy of evofosfamide in 
vivo in hypoxic tumor xenografts generated from a patient-
derived head&neck carcinoma [27].
Only recently two phase III trials of evofosfamide 
in advanced soft-tissue sarcoma and in advanced 
pancreatic cancer in combination with doxorubicin and 
gemcitabine, respectively, did not meet their primary 
endpoints of improved overall survival (CancerNetwork 
Oncology, December 2015). Our in vivo data suggest the 
treatment combination of evofosfamide with radiotherapy 
is still of strong interest but requires detailed efficacy- 
and mechanistic-oriented studies towards a successful, 
personalized treatment approach. Our data demonstrate 
that both tumor hypoxia and the POR-status are strong 
co-determinant for the efficacy of evofosfamide. Thus, 
specific image- and gene expression-guided biomarker 
analysis to determine tumor hypoxia but also HAP-
activation are required for optimized patient stratification. 
Serial analysis of serum factors specifically released in 
response to evofosfamide could represent a valid strategy 
to identify at an early stage evofosfamide-responsive 
tumors. We probed several angiogenesis- and hypoxia-
related serum factors in response to evofosfamide. 
Interestingly only secretion of the placental growth factor 
(PlGF) was increased on treatment by evofosfamide under 
hypoxia and only by the evofosfamide-responsive and not 
by the evofosfamide-resistant carcinoma cells. Our in vitro 
data also corroborate that evofosfamide in combination 
with IR is more potent in BRCA2-deficient tumor cells 
than in their BRCA2-wildtype counterpart cells. Previous 
studies were only performed in genetically-defined CHO-
cells and in combination with cisplatinum against tumor 
cells [18, 19].
Thus, it will be of highest interest to follow the 
results of the first clinical study by Larue and colleagues, 
testing evofosfamide with preoperative chemoradiotherapy 
in oesophageal adenocarcinoma patients [28]. This 
study includes repeated hypoxia PET imaging and blood 
sampling to determine hypoxia blood markers and could 
also incorporate testing of POR, PlGF and a putative 
homologous recombination-corrupted genetic background 
as part of their translational endpoints. Investigated dose 
levels of evofosfamide will range from 120 mg/m2 to 340 
mg/m2 in this clinical study. However, it will be difficult 
to compare these dose levels with the drug concentrations 
applied in our animal study due to the differential route of 
drug administration and the differential drug metabolism 
between humans and mice. For comparative reasons we used 
similar concentrations of evofosfamide doses in our study as 
in the previous preclinical study by Peters et al. [15].
Overall our data demonstrate that evofosfamide 
with IR is a potent combined treatment modality 
against hypoxic tumors. Our preclinical data suggest 
that its efficacy on the clinical level could eventually be 
dependent on scheduling parameters and tumor type. 
Furthermore, several conditions linked to the individual 
geno- and phenotype of the tumor including the status of 
the HAP-activating oxidoreductases, DNA-damage repair 
machineries and the hypoxic burden have to be fulfilled, 
rendering this combined treatment modality highly potent 
towards a personalized treatment approach.
MATERIALS AND METHODS
Cell lines and compounds
The human non-small cell lung cancer (NSCLC) 
cell line A549 was obtained from ATCC and cultured in 
RPMI 1640 cell culture media supplemented with 10% 
FBS, glutamine (2 mM) and penicillin-streptomycin 
(100 U/ml-100 μg/ml). The head&neck squamous cell 
carcinoma (HNSCC) UT-SCC-14 cell line was a kind 
gift from Reidar Grénman (Turku University Hospital, 
Finland) and was maintained in DMEM, high glucose, 
NEAA, 10% FCS, 2 mM L-glutamine, 1% Penicillin/
Streptomycin (100 U/ml-100 μg/ml) and 1 mM sodium 
pyruvate [27]. The ovarian cancer cells PEO4 and 
PEO1 were purchased from the Health Protection 
Agency Culture Collections (Salisbury, UK) and were 
kept in RPMI 1640 cell culture media supplemented 
with 10% FBS, glutamine (2 mM), sodium pyruvate (2 
mM) and penicillin-streptomycin (100 U/ml-100 μg/
ml). For normoxic conditions, cells were kept in a 5% 
CO2 incubator at 37°C, for hypoxic conditions, cells 
were kept in a 0.2% O2, 5% CO2, incubator (In vivo2 
300-Ruskinn; Hypoxia Incubator, Siemens) at 37°C. 
Evofosfamide was obtained from Merck KGaA.
Cell proliferation and clonogenic cell survival 
assay
The proliferative activities of tumor cells were 
assessed in 96-well plates with the colorimetric 
alamarBlue assay (Invitrogen). Cells were preincubated 
under hypoxia and treated for the indicated time intervals 
and concentrations of evofosfamide in either normoxic 
39
Oncotarget23710www.impactjournals.com/oncotarget
(21% O2) or hypoxic (0.2% O2) conditions. Clonogenic 
cell survival was determined by the ability of single cells 
to form colonies in vitro as described before [29]. Cells 
were treated with 0.5 μM of evofosfamide for 4 hours in 
either normoxic (21% O2) or hypoxic (0.2% O2) conditions 
or as described in the figure legend. Thereafter cells were 
reoxygenated and irradiated with increased doses of IR 
and trypsinized. To probe the adjuvant scheduling, cells 
were first irradiated with 2 Gy, followed by addition of 
evofosfamide and incubation of cells in either normoxic 
or hypoxic conditions for 4 hours. Single cell suspensions 
were seeded into 10 cm-petri dishes. The number of plated 
cells per dish was adjusted to obtain approx. 50-100 
colonies under all experimental conditions. After colony 
formation (depending on cell lines, approx. 14 days), 
colonies were fixed (methanol/acetic acid; 3:1) and stained 
with crystal violet (2%). Colonies (containing > 50 cells) 
were then counted manually.
Tumor xenografts and application of treatment 
regimes
A549 lung carcinoma and UT-SCC-14 head&neck 
squamous cell carcinoma cells were subcutaneously 
injected on the back of four week old, female CD1 
athymic nude mice (Charles River). Tumor volumes were 
determined from caliper measurements of tumor length 
(L) and width (l) according to the formula (L x l2)/2. 
Treatment was initiated when tumors reached a volume 
of 300 mm3 +/- 10%. Tumors were sham-irradiated or 
irradiated using a customized shielding device with either 
a fractionated (3x2 Gy) or a single high dose regimen 
(1x10 Gy) using an Xstrahl 200 kV X-ray unit at 1 Gy/
min. Evofosfamide (50 mg/kg in saline) or saline was 
administered i.p. Q3Dx5. Three treatment regimens were 
investigated: neoadjuvant, with evofosfamide on days 1-12 
followed by either a fractionated or a high dose regimen; 
concomitant, with evofosfamide on days 1-12 and IR on 
days 5-7 (fractionated) or day 6 (high dose); adjuvant, IR 
on days 0-2 (fractionated) or day 0 (high dose) followed 
by treatment with evofosfamide. All in vivo experiments 
were performed according to the guidelines for the welfare 
and use of animals of the Veterinäramt Kanton Zürich, 
Switzerland.
Bio-plex multiplex assay
A549 lung carcinoma and UT-SCC-14 head&neck 
squamous cell carcinoma cells were seeded in 6-well 
plates at the density of 150-200’000 cells/well in 
DMEM medium (high glucose, NEAA, 10% FCS, 2 
mM L-glutamine, 1% Penicillin/Streptomycin and 1 
mM sodium pyruvate). Cells were irradiated with 5 Gy 
followed by addition of evofosfamide (0.5; 1 μM) and 
placed in either normoxic (21% O2) or hypoxic conditions 
(0.2% O2). After 24 hour incubation, conditioned medium 
was collected, filtered through an 0.45 μM filter and 
stored at -20° C until analysis. A customized Bio-plex 
Biomarker Cancer Panel assay was performed with 
undiluted conditioned medium samples according to the 
manufacturer protocol (Bio-Rad). Obtained concentrations 
of measured samples (pg/ml) were normalized to the 
cell number and are shown as fold induction relative to 
the determined concentrations derived from normoxic 
untreated control samples.
Western blotting and immunohistochemistry
For western blot analysis, A549 and UT-SCC-14 
cells were incubated in either normoxic (21% O2) or 
hypoxic conditions (0.2% O2) for 24 hours, followed by 
lysis in RIPA buffer (Sigma) and SDS-PAGE. Membranes 
were incubated with primary anti-Cytochrome P450 
Reductase (POR/CYPOR) antibodies (Santa Cruz 
Biotechnology (G-5): sc-25263; 1:100) and mouse 
monoclonal anti–β-actin antibody (Sigma Aldrich, 
#A5441, 1:1000), followed by secondary anti-mouse 
ECL IgG HRP-linked (GE Healthcare, NA931V, 1:2000). 
Immunohistological endpoints were analyzed on paraffin-
embedded blocks of A549 and UT-SCC-14-derived tumor 
xenografts using anti-POR (Invitrogen, PA5-27326; 1:100) 
and anti-pimonidazole (Hypoxyprobe, HP1-1000, 1:100) 
antibodies.
γH2AX and 53BP1 foci staining
A549 cells were preincubated in hypoxic conditions 
(0.2% O2) for 20 hours, followed by treatment with 
evofosfamide for 4 hours under hypoxic conditions, 
reoxygenation and irradiation with 2 Gy. 20 hours after 
irradiation, cells were washed twice with PBS, fixed with 
4% formaldehyde/PBS for 10 min, and washed with PBS 
(4 x 5 min). Cells were then permeabilized for 5 min with 
0.2% ice cold Triton-X-100/PBS, blocked for at least 
20 min with 1% BSA, followed by 1 hour incubation 
with the rabbit monoclonal anti-H2AX-pSer139 (1:100, 
Abcam, Cambridge, UK) or the rabbit polyclonal anti-
53BP1 (1:200, Cell Signaling, Boston MA, USA) primary 
antibodies, diluted in 1% BSA/PBS. After washing 
with 1% BSA/PBS (3 x 15 min), cells were incubated 
with the appropriate secondary antibody diluted 1:1000 
(Alexa-488), washed with 1% BSA/PBS (2 x 10 min) 
followed by PBS (1 x 10 min) and incubated with DAPI/
Methanol (1 μg/ml) for 3 min, before fixation with Dako 
Fluorescent Mounting Medium (Dako, North America). 
Images were taken using a Leica DM 5500 microscope at 
a magnification of 40x and quantified using FociCounter 
software. At least 50 cells/condition were analyzed.
Analysis of cellular senescence
A549 cells were preincubated in hypoxic conditions 
(0.2% O2) for 20 hours, followed by treatment with 
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evofosfamide for 4 hours under hypoxic conditions, 
reoxygenation and IR with 2 Gy. 72 hours after 
irradiation, cells were stained for β-galactosidase using the 
Senescence β-Galactosidase Staining Kit (Cell Signaling, 
#9860): cells were washed with PBS and fixed (with 2% 
formaldehyde, 0.2% glutaraldehyde in PBS) for 15 min 
at room temperature. Cells were washed twice with PBS 
and stained with 40 mM citric acid/sodium phosphate 
(pH 6.0), 0.15 M NaCl, 2 mM MgCl2, 5 mM potassium 
ferrocyanide, 5 mM potassium ferricyanide, 1 mg/ml 
X-gal (5-bromo-4-chloro-3-indolyl-βD-galactopyranoside) 
for 24 hours at 37°C. β-galactosidase-positive cells were 
counted in at least 3 randomly chosen visual fields at a 
magnification of 10x in each treatment setup.
Short interfering RNA treatment
A549 cells were transfected with POR-directed 
siRNA (Santa Cruz Biotechnology) for 24h using 
Lipofectamine RNAiMAX (Invitrogen). Cells were 
preincubated under hypoxia (0.2% O2) for 20 hours, 
followed by incubation with evofosfamide for 4 hours 
under hypoxia and reoxygenation.
Statistical analysis
For in vivo treatment response to evofosfamide 
with fractionated and single high dose irradiation, the 
mean slopes of tumor growth curves for individual 
animals (day 0-15) were calculated and analyzed by one 
way ANOVA with Tukey post test using the GraphPad 
software. To calculate statistical significance between two 
or more groups of variables in in vitro experiments, either 
unpaired t-test or ANOVA with Tukey post test was used, 
respectively. P values <0.05 were considered significant. 
For all experiments, *P<0.05, **P<0.01, ***P<0.001.
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Supplementary Figure 1: Tumor hypoxia in A549 and UT-SCC-14-derived tumor xenografts. Staining of A549 (left) and 
UT-SCC-14 (right)-derived tumor xenografts for pimonidazole uptake. Pimonidazole was injected 1 hour (i.p.) prior euthanasia and tumor 
extraction.
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Supplementary Figure 2: Differential sensitivity of A549 and UT-SCC-14 cells to evofosfamide in vitro. Proliferative 
activity of A549 and UT-SCC-14 cells 72 hours after evofosfamide treatment. Cells were preincubated under hypoxia (0.2% O2) for 20 
hours, followed by treatment with increasing concentrations of evofosfamide for 4 hours, followed by reoxygenation. Error bars represent 
SEM.
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Supplementary Figure 3: Effect of POR downregulation on A549 cell sensitivity towards evofosfamide in vitro. 
Proliferative activity of siLUC and siPOR-pretreated A549 cells 48 hours after evofosfamide treatment. Cells were preincubated under 
hypoxia (0.2% O2) for 20 hours, followed by treatment with evofosfamide (0.5μM) for 4 hours and reoxygenation. Error bars represent 
SEM.
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Supplementary Figure 4: Analysis of secreted factors in response to evofosfamide and irradiation. Raw data of Bioplex 
analysis of secreted factors in A549 and UT-SCC-14 cells in reponse to evofosfamide (0.5, 1 μM) and irradiation (5 Gy) under normoxic 
(21% O2) and hypoxic conditions (0.2% O2). Error bars represent SEM.
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Supplementary Figure 5: DNA damage in response to evofosfamide and irradiation. 53BP1 foci were analyzed in A549 cells 
treated for 4 hours with evofosfamide and irradiation with 2 Gy. Cells were analyzed 20 hours after irradiation. Error bars represent SEM.
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Supplementary Figure 6: Luciferase-activity of A549 ODD-Luc-derived tumor xenografts untreated and treated with 
single high-dose IR (20 Gy). Representative in vivo bioimages of control and irradiated mice. Measurements were performed as 
described in [1]. Data are shown as fold induction of the total flux normalized to the tumor volume at the indicated time point. Error bars 
represent SEM.
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Abstract 
Purpose: Tumor hypoxia is a major limiting factor for successful radiotherapy outcome. Here 
we investigate the combined treatment modality of the reoxygenating compound myo-inositol 
trispyrophosphate (ITPP) in combination with ionizing radiation (IR) in preclinical animal 
tumor models. 
Experimental Design: ITPP-mediated tumor reoxygenation was serially probed by a non-
invasive, hypoxia-directed luciferase-based bioimaging approach in tumor xenografts derived 
from FaDu head and neck squamous carcinoma (HNSCC) and A549 non-small cell lung 
carcinoma (NSCLC) cells. The efficacy of ITPP in combination with irradiation was 
determined in vitro and in vivo. Initial and residual DNA-damage- and tumor 
microenvironment-oriented endpoints in response to treatment were determined by 
immunohistochemistry. 
Results: ITPP-dependent tumor reoxygenation could be detected in the HNSCC- and the 
NSCLC tumor models already 2 hours following ITPP bolus application. ITPP alone did not 
affect cellular radiosensitivity in vitro and tumor growth in vivo, but significantly reduced 
tumor growth when combined with single high dose fractions of IR. Immunohistochemical 
analysis of γH2AX foci demonstrated increased initial and residual DNA damage within 
initially hypoxic tumor regions after combined treatment with ITPP and IR in comparison to IR 
alone. Interestingly, increased tumor hypoxia and vascular damage was detected 4 days after 
irradiation alone, which were both prevented by the combined treatment with ITPP and thereby 
exploitable for second high dose fraction of IR. 
Conclusions: Our investigations on the combined treatment modality of ITPP with irradiation 
demonstrate an immediate tumor oxygenating and secondary tumor vasculature protective 
effect of ITPP, with subsequently increased IR-induced DNA damage and tumor-oriented 
cytotoxicity.  
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Introduction 
Approximately 50% of all cancer patients receive radiotherapy, either alone or in combination 
with surgery or chemotherapy (1). One of the major obstacles for successful treatment outcome 
is tumor hypoxia due to enhanced radiation resistance in low oxygenated tumor areas (2), with 
hypoxic cells being up to three fold more radiation resistant than normoxic cells. Classic 
radiotherapy protocols use low dose fractionated treatment regimens, which exploit partial 
reoxygenation of hypoxic tumor areas in between daily fractions of  radiotherapy to reduce the 
hypoxic, radiation resistant tumor burden.(3).  
Hypoxic tumors arise as a result of inadequate perfusion due to structural and functional 
abnormalities of the tumor microvasculature, which is mainly caused by overexpression of the 
vascular endothelial growth factor (VEGF) in tumor tissues (4,5). Attempts to prevent and 
reverse a chaotic microvasculature and to subsequently reduce tumor hypoxia include the 
clinically relevant anti-VEGF-directed monoclonal antibody bevacicumab (Avastin). However, 
clinical trials combining radiotherapy with bevacizumab failed to be of significant clinical 
benefit (6,7). More recently, normalization of the tumor vasculature was successfully shown to 
be induced by inhibitors of classic signal transduction cascades. With this rational, agents 
targeting the EGFR/PI3K/Akt-pathway, are also tested in tumor xenografts in combination with 
ionizing radiation (8,9).    
Constant improvements of imaging and linear accelerator technology have resulted  in  high 
conformity irradiation of the tumor, which nowadays allows hypofractionation and stereotactic 
body radiation therapy (SBRT) (10). However, SBRT and hypofractionation with only a few 
high dose fractions of radiotherapy does not anymore exploit iterative reoxygenation in between 
fractions. To achieve tumor control and to further minimize normal tissue toxicity, a combined 
treatment modality with pharmaceutical compounds that preferentially kill the hypoxic tumor 
burden, such as hypoxia-activated prodrugs, or that increase the partial oxygen pressure and 
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normalize the tumor vasculature in the tumor is of even higher interest when combined with 
SBRT and hypofractionation (11).  
Myo-inositol trispyrophosphate (ITPP) was developed as an allosteric effector of hemoglobin 
(12) and potentially combines several of the above described mechanisms to overcome tumor
hypoxia. ITPP is actively taken up by red blood cells and triggers a decrease of the affinity of 
oxygen to hemoglobin, which leads to an increased release of oxygen upon tissue demand i.e. 
in hypoxic tumors (12,13). Subsequent to this rapidly induced and persistent physicochemical 
effect, ITPP normalizes the tumor vasculature on downregulation of pro-angiogenic factors like 
HIF-1α and VEGF. (14). In addition, ITPP selectively activates the tumor suppressor PTEN in 
endothelial cells thereby inhibiting signaling downstream of PI3K and subsequently 
normalizing the tumor vasculature (15). 
Here we investigated the impact of ITPP on the DNA damage response and on tumor hypoxia, 
and probed the combined treatment modality of ITPP in combination with hypofractionated 
radiotherapy in a lung adenocarcinoma and head&neck carcinoma tumor model.  
Material and Methods 
Cell culture and compounds 
The human head&neck squamous cell carcinoma (HNSCC) cell line FaDu was obtained from 
ATCC and cultured in EMEM cell culture medium supplemented with 10% FBS and 1% 
penicillin-streptomycin at 37°C in 5% CO2. The human non-small cell lung cancer (NSCLC) 
cell line A549 was obtained from ATCC and maintained in RPMI 1640 cell culture medium 
supplemented with 10% FBS, 1% L-glutamine and 1% penicillin-streptomycin at 37°C in 5% 
CO2. Myo-inositol trispyrophosphate (ITPP) was provided by NormOxys and dissolved in PBS. 
Tumor xenografts and application of treatment regimens 
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FaDu HNSCC and A549 NSCLC cells (4 x 106 cells/150 µL saline) were subcutaneously 
injected in the back of 4-week old, female athymic CD1 nude mice (Charles River). Tumor 
volumes were determined by caliper measurements of tumor length (L) and width (l) according 
to the formula (L x l2)/2. Treatment was started when tumors reached a volume of 300 mm3 ± 
10%. ITPP (dissolved in PBS) was administered intraperitoneally at 3 g/kg on two consecutive 
days. Tumors were sham-irradiated or irradiated using a customized shielding device with 
either 1 x 10 Gy (2 hours after second ITPP injection) or 2 x 10 Gy (2 hours after second ITPP 
injection, 5 days after second ITPP injection). All in vivo experiments were performed 
according to the guidelines for the welfare and use of animals of the Veterinäramt Kanton 
Zürich, Switzerland. 
 
Irradiation  
If not stated differently, irradiation was performed using an Xstrahl 200 kV X-ray unit at 1 
Gy/min. For ionizing radiation (IR)-induced DNA damage analysis in FaDu xenografts and for 
the tumor growth delay experiment in A549 xenografts, an image-guided small animal 
radiotherapy platform (Precision X-Ray, X-Rad SmART) 225 kV unit with a dose rate of 3 
Gy/min was used. 
 
Cell proliferation and clonogenic survival assay 
The proliferative activities of tumor cells were assessed in 96-well plates with the colorimetric 
alamarBlue assay (Invitrogen). Clonogenic cell survival was determined by the ability of single 
cells to form colonies in vitro as described previously (16). Briefly, cells were treated with ITPP 
or vehicle for 6 hours. Thereupon, cells were irradiated with increasing doses of IR, trypsinized 
and reseeded in petri dishes. After 14 days, colonies were fixed (methanol/acetic acid 3:1) and 
stained with crystal violet (2%). Colonies were then counted manually. 
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 Western blotting 
For sample preparation, cells were detached in Lämmli Buffer, heated for 5 minutes at 95°C 
and their protein concentration was determined by Nanodrop 1000 (Spectrophotometer, 
Thermo Scientific). The samples were size separated by SDS-PAGE and transferred to a 
polyvinylidene difluoride (PVDF) membrane using a semi-dry transfer unit (TE70X, Hoefer). 
After the transfer, membranes were blocked in 5% non-fat milk solution (NFMS) for 1 hour at 
room temperature before overnight incubation at 4°C with different primary antibodies (pAKT 
(Ser473) Cell Signaling, PTEN (138G6) Cell Signaling, PI3K (p110 α) Upstate Biotechnology, 
β-actin Sigma Aldrich, 1:1000 in 5% NFMS). Membranes were probed for primary antibody 
with anti-rabbit (1:2000) and anti-mouse (1:2000) ECL peroxidase conjugates. 
Chemiluminescence was identified with ECLTM Western Blotting detection agents by a Vilber 
Lourmat Fusion FX Detector. 
In vivo bioluminescence imaging and analysis 
FaDu and A549 cell lines were transfected with SV40-luciferase and SV40-ODD-luciferase 
vectors as described previously (17). Tumor-bearing mice were intraperitoneally (i.p.) injected 
with 150 mg/kg D-Luciferin (Perkin Elmer) 5 minutes before anesthesia. Sequential 
measurements of photon emission (flux/s) were acquired approximately 10 minutes after D-
Luciferin injection with the IVIS200 (Xenogen). The measurement with the highest photon flux 
within the tumor of each mouse was used for the pharmacodynamic survey. The values were 
normalized to the baseline value (t=0) and divided by the tumor volume. 
Immunohistochemistry 
Immunohistological endpoints were analyzed on formalin-fixed paraffin-embedded (FFPE) 
blocks for hematoxyline & eosine, pimonidazole (1:12000, Hypoxyprobe), CAIX (1:6000, 
abcam, ab184006), CD31 (1:10, Dako, M0823), SMA (1:50, Dako, M0851) and γH2AX 
(1:500, Novus Biologicals, NB100-2280). Viable areas (as determined by H&E staining) of 
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whole tumor sections were manually quantified for specific pimonidazole or CAIX staining 
percentage. Number of blood vessels (CD31) and their respective SMA coverage were counted 
in at least 3 randomly chosen visual fields (magnification 100x) in each xenograft. 
IR-induced DNA damage analysis 
FaDu xenograft-bearing mice received 60 mg/kg pimonidazole 4 hours prior to the previously 
established treatment schedule, i.e. 3g/kg ITPP or PBS on 2 consecutive days, followed by a 
single fraction of 4 Gy. Tumors were harvested 30 minutes or 24 hours after IR, immediately 
fixed in formalin and embedded into paraffin 24 hours thereafter. Three consecutive 3 µm tissue 
sections were stained for H&E, pimonidazole and γH2AX. For the evaluation, 3 hypoxic 
(pimonidazole-positive) and 3 normoxic (pimonidazole-negative) areas per tissue section were 
selected and the individual number of γH2AX foci per nucleus was counted in at least 100 cells 
of the chosen area. The individual number of foci per cell was normalized to the according 
nuclear volume using ImageJ. Foci analysis was performed in viable, non-dividing cells only.  
Statistical analysis 
In vivo luciferase activity data were analyzed by Student’s t-test. For the treatment response to 
ITPP in combination with IR, the time to reach a tripling of the initial tumor volume (T3xSV) 
was analyzed by one-way ANOVA with Tukey post test. Immunohistochemical data were 
analyzed by one-way ANOVA on replicate tumor samples (n =3) and pair-wise analysis was 
performed using the Tukey test. 
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Results 
To monitor tumor reoxygenation on ITPP administration we used a functional hypoxia-oriented 
luciferase-based reporter gene assay, which was previously developed in our laboratory (17). 
Briefly, the oxygen-dependent degradation (ODD) domain of HIF-1α is fused 5` to the 
luciferase reporter gene. The construct in constantly expressed in cells under control of a 
hypoxia-independent SV40 promoter.  In the presence of oxygen, the SV40-ODD-Luc 
construct is degraded, resulting in low bioluminescent photon flux upon luciferin 
administration. The tumor oxygenation status was determined at different timepoints after 
intraperitoneal ITPP (3 g/kg) injection in stably transfected lung adenocarcinoma (A549) and 
head&neck squamous cell carcinoma (FaDu) tumor xenograft models. These cell lines were 
previously shown to develop xenografts with high (A549) and intermediate (FaDu) hypoxic 
tumor fractions (18,19). The first measurements were performed when tumors reached a volume 
of 300 mm3 (± 10%). 
In the more hypoxic A549 xenograft model, tumor oxygenation was significantly increased 
already 2 hours after intraperitoneal ITPP administration (Fig. 1A). The hypoxic tumor fraction 
was decreased 2.2-fold as compared to the initial baseline level. Serial measurements of tumor 
oxygenation revealed a time-dependent, partial reversion of tumor hypoxia. ITPP-mediated 
tumor reoxygenation was stable for up to 10 hours after ITPP injection (Supplementary Fig. 
S1). Only minimal changes in luminescence were detected in A549-derived tumor xenografts 
expressing the ODD-luciferase reporter gene on administration of PBS.  
To validate that ITPP-induced changes in luciferase activity are mediated by alterations in 
tumor oxygenation, we determined luminescence in tumor xenografts derived from A549 cells 
stably transfected with a SV40-Luc construct lacking the oxygen-dependent degradation 
domain (ODD). Neither PBS- nor ITPP-administration affected luciferase activity in these 
control tumors (Fig. 1B).   
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To determine the capacity of ITPP to reoxygenate tumors with a lower hypoxic fraction, we 
probed the previously developed treatment schedule in FaDu-derived xenografts also 
expressing the ODD-luciferase construct. ITPP-mediated reoxygenation of FaDu xenografts 
was less effective in comparison to the response observed in the lung adenocarcinoma derived 
tumor xenograft, which most probably due to their lower hypoxic fraction. Nevertheless, a 
significant decrease in tumor hypoxia was detected 2 hours after the second ITPP administration 
(p = 0.03), whereas PBS treatment had no impact on tumor oxygenation (Fig. 1C). Overall, 
these results demonstrate that ITPP efficiently reoxygenates hypoxic tumors in a dose-and time 
dependent manner. 
 
Increased tumor response to radiotherapy in combination with ITPP  
The tumor response to a combined treatment modality of ITPP and IR was determined in the 
A549-derived tumor xenograft model that was treated on two consecutive days with ITPP (3 
g/kg) and PBS, respectively,  followed by a single dose of IR (5 Gy) 2 hours after the second 
ITPP administration. While tumor growth was not affected by treatment with ITPP alone, 
irradiation induced a tumor growth delay that was further extended in ITPP-pretreated tumors.  
The time to reach 2.5fold of the initial tumor volume (300 mm3) was significantly delayed by 
administration of ITPP prior to a single high dose of irradiation in comparison to IR alone (31 
versus 22 days, p = 0.01), with many tumors becoming necrotic thereafter (Fig. 2A). To 
investigate the tumor response in the less hypoxic FaDu-tumor cell derived tumor model, mice 
were treated with the same treatment schedule as for the A549-derived tumor xenograft model, 
but received a higher dose of IR (1 x 10 Gy) due to the lower radiosensitivity of FaDu cells in 
comparison to A549 cells. ITPP alone did not affect tumor growth rate, whereas neoadjuvant 
administration significantly enhanced the time to triple the initial tumor volume at treatment 
start in comparison to IR alone (p = 0.03) (Fig. 2B). Overall, these results demonstrate that 
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ITPP reoxygenate hypoxic tumors and enhance the treatment response to a single dose of 
ionizing radiation.  
ITPP does not enhance cellular response to ionizing radiation in vitro.  
Given its structural relationship to the substrates of the phosphatidylinositol-4,5-bisphosphate 
3-kinase (PI3K) family, ITPP could interfere with cellular  PI3K/AKT signalling, which is
important for tumor cell proliferation and cellular radiation sensitivity (20) and unpublished 
Data by NormOxys). Interestingly, we observed a time-dependent decrease in phosphoAKT 
levels in cell lysates derived from ITPP treated A549 and FaDu cells (Fig. 3A). Furthermore, 
decreasing phosphoAKT levels correlated in FaDu but not in A549 cells with increasing 
Phosphatase and tensin homolog (PTEN) protein levels, which is known to counteract PI3K-
signaling. Since high phosphoAKT levels are associated with increased radioresistance (21) 
cell proliferation and clonogenic cell survival assays were performed on combined treatment 
with ITPP and ionizing radiation. Increasing concentration of ITPP did not affect cellular 
proliferative activity and did not enhance cellular sensitivity of A549 and FaDu cells to IR (Fig. 
3B and 3C). These results strongly suggest that increased ITPP-mediated tumor growth delay 
in response to irradiation is primarily caused by neoadjuvant tumor reoxygenation prior to 
irradiation. 
ITPP increases IR-induced DNA damage in hypoxic tumor areas 
Increased ITPP-mediated oxygen availability within the tumor at the timepoint of irradiation 
could result in the generation of a differential amount of DNA double strand breaks (DSB) in 
response to IR. Therefore the initial and residual amount of γH2AX-foci were assessed in FaDu-
derived xenografts that were treated with PBS and ITPP, irradiated with a single IR-dose of 4 
Gy and harvested 30 minutes and 24 hours, respectively, after irradiation. A reduced dose of 4 
Gy was applied since the amount of γH2AX-foci induced after 10 Gy was technically not 
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feasible to count (22,23). Pimonidazole was injected 4 hours prior to our established treatment 
regimen to covalently label initially hypoxic tumor areas and to identify them retroactively after 
treatment and tumor harvesting. (Fig. 4A). 
Within initially hypoxic tumor regions, the average number of γH2AX foci per nucleus 
detectable 30 minutes after irradiation was 22.8 ± 3.7. A significantly increased number of 
γH2AX foci per nucleus (34.3 ± 4.9, p = 0.0006) was determined in neoadjuvant ITPP-treated 
and irradiated tumors that were harvested at this early time point. Moreover, frequency 
distribution analysis revealed that in almost 10% of irradiated hypoxic tumor cells no γH2AX-
foci were detectable, whereas less than 1% of cells remained undamaged after ITPP-treatment 
and irradiation (Fig. 4B). To validate that ITPP specifically increases DNA damage in hypoxic 
tumor cells, initially normoxic, pimonidazole-negative areas were analysed for γH2AX foci. As 
expected, the average number of γH2AX foci per nucleus after PBS and IR treatment was higher 
in these normoxic cells (31.6 ± 6.7) in comparison to hypoxic cells (see above) but was not 
significantly further increased in ITPP-pretreated tumors (37.1 ± 4.5, p = 0.09). The frequency 
distribution of γH2AX-foci in the ITPP- and PBS-pretreated, pimonidazole-negative areas was 
similar,  indicating a DNA-damage enhancing effect of ITPP specifically in the pimonidazole-
positive, pretreatment hypoxic tumor areas (Fig. 4C).  
Eventually it is the amount of residual DNA damage, which is relevant for irradiation-induced 
cell death.  The average number of residual γH2AX foci per cell in initially hypoxic, 
pimonidazole-positive tumor areas was significantly higher in ITPP versus PBS-pretreated 
tumors (31.3 ± 4.2 vs 17.5 ± 4.0, respectively; p = 0.0001). The amount of residual γH2AX foci 
per cell in normoxic, pimonidazole-negative tumor  areas was also higher in ITPP versus PBS-
pretreated tumors, but not to an extent as determined in the initially hypoxic and ITPP-
reoxygenated tumor areas (28.9 ± 5.3 vs 21.7 ± 5.2, respectively; p = 0.003; compare Fig. 4D 
and 4E). This partial ITPP-related effect in normoxic areas might be due to a slight increase of 
the pO2 at a pO2-level not sufficiently low for pimonidazole staining.  Overall, these results 
61
illustrate the higher incidence of DNA damage induced in ITPP-pretreated tumors in particular 
in initially hypoxic tumor areas, which is most probably the key source for enhanced IR-
efficacy in ITPP-pretreated tumors.  ITPP treatment without subsequent irradiation has no effect 
on the number or distribution of induced DNA DSBs (Supplementary Fig. 2).  
ITPP protects from IR-induced vascular damage and IR-enhanced tumor hypoxia 
Single high dose irradiation damages the tumor vasculature with subsequently increased tumor 
hypoxia (24,25). On the other hand ITPP treatment was previously shown to normalize the 
tumor vasculature (15). Therefore a differential treatment-induced effect on the tumor 
microenvironment was determined after ITPP-treatment (on two consecutive days, 3 g/kg) and 
irradiation (10 Gy) alone and in combination in FaDu-derived tumor xenografts at the time 
point 5 days after treatment start.   
Tumor irradiation resulted in decreased microvessel  density (MVD; CD31-positive vessels per 
visual field) in comparison to the MVD in unirradiated tumors of PBS-treated mice (113 ± 34 
vs 74 ± 37; p = 0.01). Interestingly, irradiation-induced vascular damage (vessels/field) was 
completely prevented in tumors of mice pretreated with ITPP [103 ± 32 (ITPP) vs. 112 ± 41 
(ITPP + IR), p = 0.93] (Fig. 5A). Likewise, pericyte coverage of CD31-positive vessels in 
control tumors decreased on irradiation, but remained stable in ITPP-pretreated tumors (Fig. 
5B). Staining for carbonic anhydrase IX (CAIX) was used to determine tumor hypoxia in 
response to treatment. The hypoxic tumor fraction increased from 7.2 ± 4.7%  to 11.1 ± 5.2% 
during 4 days after irradiation, but remained low in ITPP-pretreated tumors (5.1 ± 1.5% before 
vs 5.0 ± 2.5% after irradiation)  (Fig. 5C). The protective ITPP-related effect could also be 
observed on staining for the exogenous hypoxia marker CCI-103F (Fig. 5D). These results 
indicate that ITPP protects the tumor vasculature from high dose ionizing radiation-induced 
damage. 
62
To exploit the tumor vasculature-protective effect of ITPP and subsequently altered tumor 
microenvironment, FaDu-derived xenografts were irradiated with a second high dose fraction 
of 10 Gy 4 days after the initial treatment sequence. The second fraction of IR further delayed 
tumor growth of ITPP and IR-pretreated tumors in comparison to IR-pretreated tumors alone 
(Fig. 6A and see also Fig. 3C above, p = 0.02). Moreover, the tumor vasculature-oriented 
protective effect of ITPP remained effective even after the second high-dose fraction of IR. The 
MVD of mice receiving irradiation alone (2 x 10 Gy) was reduced from 77 ± 21 to 40 ± 14 (p 
= 0.004) CD31+-vessels/field 9 days after treatment start. In contrast, initial ITPP treatment 
prevented an MVD-decrease even after two high dose fractions of irradiation [60 ± 26 (ITPP 
alone) vs. 67 ± 22 (ITPP plus IR), p = 0.94] (Fig. 6C).  
Overall, our investigations on the combined treatment modality of ITPP with irradiation 
demonstrate an immediate oxygenating and delayed tumor vasculature protective effect of 
ITPP, with subsequently increased IR-induced tumor-oriented cytotoxicity.  
 
Discussion 
Only limited approaches exist to reduce the hypoxic tumor burden for successful radiotherapy. 
Classic fractionated radiotherapy regimens exploit reoxygenation in between individual 
fractions, which can be further enhanced e.g. as part of a combined treatment modality with 
nicotinamide and carbogen breathing. But novel approaches are of great need to either reverse 
or to exploit tumor hypoxia as part of high dose hypofractionated and stereotactic body 
radiotherapy, in particular since high dose fractions of ionizing radiation might even further 
enhance tumor hypoxia (new references). (6,7,26-29). Here, we probed to enhance the radiation 
response with myo-inositol trispyrophosphate (ITPP) and identified by invasive and non-
invasive approaches that hypoxic tumor xenografts were rapidly reoxygenated on ITPP 
administration. Subsequent irradiation of the reoxygenated tumor xenografts significantly 
delayed tumor growth as compared to tumor irradiation alone, while ITPP alone did not 
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interfere with tumor growth. Immediate ITPP-induced reoxygenation resulted in an enhanced 
level of both IR-induced and residual DNA damage in these pretreatment hypoxic areas, which 
are most probably the major contributing factor for the enhanced tumor response to the 
combined treatment modality. Besides this immediate effect, we demonstrated a delayed 
protective effect of ITPP on the tumor vasculature. ITPP treatment increased pericyte coverage 
of the tumor vasculature and thereby prevented RT-induced vascular damage and subsequential 
increase of tumor hypoxia, which could be further exploited by a second high dose of 
irradiation.  Overall, these results strongly support the hypothesis of Raykov et al, who 
originally postulated early and delayed antitumor-directed mechanisms of ITPP (14).  
These in vivo experiments were performed in athymic immuno-compromised mice. Thereby, a 
probable involvement of the adaptive immune system in response to high dose radiotherapy 
could be excluded, However, the protected and still intact vasculature in response to the 
combined treatment modality could promote an increased immune cell infiltration, which might 
further affect the outcome in response to ITPP in combination with high dose radiotherapy (30) 
We are currently testing this hypothesis in follow-up experiments in C57BL/6 mice.  
In vitro experiments revealed that ITPP also interferes with the PI3K/Akt-pathway and 
downregulates phosphoAkt levels in the pretreated tumor cells. However, ITPP did not increase 
the antiproliferative effect of ionizing radiation and did not enhance the radiosensitivity of 
tumor cells under normoxic conditions, thereby excluding a direct ITPP-mediated effect on 
cellular radiosensitivity. Hence, the enhanced tumor growth delay in response to the combined 
treatment modality might primarily be linked to ITPP-induced tumor reoxygenation with 
subsequently enhanced  tumor cell killing due to the increased number of induced and residual 
DNA DSBs on irradiation. Eventually, it will be of interest to apply curative treatment regimens 
of ITPP in combination with radiotherapy and to probe this combined treatment modality even 
in combination with chemotherapy and immunotherapy. 
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A combined treatment modality of ITPP in combination with chemotherapy and radiotherapy, 
respectively, has previously investigated on the preclincial level but applying different 
treatment regimens. A low dose regimen of ITPP over 10 days potentiated the capacity of 
FOLFOX chemotherapy in a hypoxic colorectal liver metastasis tumor model, which is most 
probably based on the long-term tumor vascular normalization effect of ITPP (31).  An 
extended neoadjuvant low dose regimen of ITPP was probed in an orthotopic glioblastoma 
tumor model in combination with hypofractionated  radiotherapy but failed to enhance the 
potency of radiotherapy, which might be due to lack of vascular normalization in glioblastoma 
in response to low dose of ITPP or failure of ITPP to cross the blood brain barrier as suggested 
by Förnvik et al. (32). Our data demonstrate lack of antitumor activity of ITPP alone but an 
enhanced treatment response in combination with radiotherapy, best applied as a boost 
immediately prior to radiotherapy. Own dose response investigations revealed no treatment 
enhancement with reduced dose of ITPP and delayed irradiation (Supplementary Fig. 3).   
ITPP is currently tested as part of a phase Ia/IIb clinical trial in combination with chemotherapy 
for non-resectable abdominal tumors Based on its capacity to reoxygenate hypoxic tumor and 
using tumor hypoxia-oriented image-guidance, our results support the strong rationale to 
combine ITPP also with hypofractionated radiotherapy. 
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Figure legends 
Fig. 1. ITPP induces rapid tumor reoxygenation. (A) Bioluminescent photon flux is 
significantly decreased in tumors derived from A549 cells transfected with the hypoxia reporter 
construct (SV40-ODD-Luc, n = 4-5 mice per group) 2 hours after ITPP injection, whereas PBS 
administration does not result in significant alterations. (B) Neither PBS nor ITPP treatment 
induce significant changes in bioluminescent photon flux in tumors derived from A549 cells 
transfected with the control construct (SV40-Luc, n = 3-4 mice per group). (C) Bioluminescent 
photon flux is significantly decreased in tumors derived from FaDu cells transfected with the 
hypoxia reporter construct (SV40-ODD-Luc, n = 3-4 mice per group) 2 hours after ITPP 
injection, whereas PBS administration does not result in significant alterations. Bar graphs 
represent the fold change in photon flux as compared to baseline as mean ± SEM. The students 
t-test was used to compare changes in reoxygenation.
Fig. 2. Tumor growth is delayed on combined treatment with ITPP and IR. Effect of ITPP 
in combination with IR in mice bearing A549- (A) (n = 6-9 per group) and FaDu- (B) (n = 10 
per group) derived tumors. Mice were treated with two doses of ITPP (3 g/kg, i.p.), and IR 
(single dose of 5 Gy and 10 Gy, respectively) alone and in combination. Each curve represents 
the mean tumor volume per group ± SEM. Kaplan–Meier curves for A549- (C) and FaDu- (D) 
derived tumor xenografts for reaching tripling tumor volumes (900 mm3). One-way ANOVA 
test was used to statistically compare tumor growth rates. 
Fig. 3. ITPP interferes with PI3K/AKT pathway but does not affect cellular  sensitivity to 
ionizing radiation. (A) A549 and FaDu cells were treated with ITPP (10 mM) for up to 48 
hours and whole cell lysates were analyzed against the indicated proteins by western blotting. 
(B) Relative proliferative activity of irradiated A549 and FaDu cells (5 Gy) pretreated for 24
hours with increasing concentrations of ITPP. (C) Clonogenic cell survival of A549 and FaDu 
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cells pretreated for 24 hours with PBS or ITPP (10 mM) and irradiated with increasing doses 
of IR. Data are represented as mean ± SD. 
Fig. 4. Reoxygenation by ITPP increases the number of IR-induced DNA DSBs in initially 
hypoxic tumor areas. (A) Treatment schedule and representative pimonidazole-stained tumor 
slice of a FaDu-derived tumor xenograft. γH2AX foci in control and ITPP-pretreated tumors, 
30 minutes after IR (4 Gy) in initially hypoxic (B) and normoxic (C) tumor regions. 1 dot 
represents mean of γH2AX foci/cell of at least 100 cells counted in either initially hypoxic or 
normoxic tumor regions. Representative cell nuclei and frequency distribution plots (γH2AX 
foci/cell) are also shown. γH2AX foci in control and ITPP-pretreated tumors, 24 hours after IR 
(5 Gy) in initially hypoxic (D) and normoxic (E) tumor regions. 1 dot represents mean of 
γH2AX foci/cell of at least 100 cells counted in either initially hypoxic or normoxic tumor 
regions.  Representative cell nuclei and frequency distribution plots (γH2AX foci/cell) are also 
shown. Data are represented as mean ± SD. The students t-test was used to compare numbers 
of γ-H2AX foci. 
Fig. 5. ITPP  protects from IR-induced vascular damage and increase of tumor hypoxia. 
(A) Quantification of CD31+ blood vessels per visual field 4 days after IR. Representative 
stainings are shown. (B) Percentage of SMA+ CD31+ blood vessels (pericyte coverage) of total 
amount of CD31+ blood vessel. (C) Percentage of CAIX-positive tumor area of total viable 
tumor area. Representative stainings are shown. (D) Percentage of CCI-103-F-positive tumor 
are of total viable tumor area. CCL-103-F was injected 2 hours prior to tumor collection. The 
students t-test was used to analyse data. 
Fig. 6.  Extended tumor growth delay and tumor vasculature protection on reirradiation. 
Tumor growth delay (A) and Kaplan-Meier (B)curves of FaDu-derived tumor xenografts (n = 
10 per group) pretreated with PBS or ITPP, and irradiated with the first fractions of 10 Gy, 2 
hours after the 2nd IPTT-dose and the second fraction of 4 Gy 4 days thereafter. (C) 
Quantification of CD31+ blood vessels per visual field in FaDu-derived tumor sections 4 days 
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after the second IR fraction. One-way ANOVA test was used to compare tumor growth rates. 
The students t-test was used to analyse blood vessel data. 
Supplementary Figure Legends 
Supl. Fig. 1 ITPP-mediated tumor reoxygenation in tumors is effective for up to 10 hours 
after injection. (A) Bioluminescent photon flux is decreased 2 hours after ITPP injection and 
remains low for up to 10 hours in tumors derived from A549 cells, transfected with the hypoxia 
reporter construct (SV40-ODD-Luc, n = 4-5 mice per group). (B) Neither PBS nor ITPP 
treatment induce significant changes in bioluminescent photon flux in tumors derived from 
A549 cells transfected with the control construct (SV40-Luc) (n = 3-4 mice per group). Bar 
graphs represent the fold change in photon flux as compared to baseline as mean ± SEM. 
Suppl. Fig. 2 ITPP-mediated tumor reoxygenation does not increase  the number of DNA 
DSBs in unirradiated tumors. (A) Treatment schedule. γ-H2AX foci in control and ITPP-
treated tumors in initially hypoxic (B) and normoxic (C) tumor regions. Tumors were collected 
30 minutes after treatment. 1 dot represents mean of γH2AX foci/cell of at least 100 cells 
counted in either initially hypoxic or normoxic tumor regions. Representative cell nuclei and 
frequency distribution plots (γH2AX foci/cell) are also shown. γ-H2AX foci in control and 
ITPP-treated tumorsin initially hypoxic (D) and normoxic (E) tumor regions. Tumors were 
collected 24.5 hours min after treatment. 1 dot represents mean of γH2AX foci/cell of at least 
100 cells counted in either initially hypoxic or normoxic tumor regions. Representative cell 
nuclei and frequency distribution plots (γH2AX foci/cell) are also shown. Data are represented 
as mean ± SD. The students t-test was used to compare numbers of γ-H2AX foci.  
Suppl. Fig. 3 No additional tumor growth delay in tumors treated with reduced ITPP-dose 
and delayed irradiation Effect of ITPP in combination with IR in mice bearing A549-derived 
68
tumors. Mice were treated with two doses of ITPP (1.5 g/kg, i.p.), and one IR-fraction of 10 
Gy, 24 hours after the second ITPP injection.  
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Abstract 
 
Background and purpose: The treatment of colorectal liver metastases by SBRT is currently 
under clinical investigation. Remarkably, this exact treatment approach has not yet been 
reported on the preclinical level. Here, we developed an irradiation strategy for murine 
colorectal liver metastases that enables to study combined treatment modalities and thereby 
improve the treatment options in the clinical situation. 
Materials and methods: We generated an animal model for colorectal liver metastases, 
affecting exclusively the right liver lobe by selective portal vein injection of murine MC-38 colon 
carcinoma cells. The metastasized liver lobe was visualized by contrast-enhanced cone beam 
CT imaging and irradiated with an image-guided small animal radiotherapy platform. MRI was 
applied to follow volumetric changes in colorectal liver metastases after SBRT. 
Results: Selective intraportal injection of colorectal cancer cells yields a high rate in liver 
metastasis formation. Targeted irradiation of the right liver lobe with single fractions of 10 and 
15 Gy is effective in reducing the growth of metastatic lesions without causing radiation-
induced toxicities. 
Conclusion: We present a robust and reproducible preclinical colorectal liver metastases 
model and image-guided irradiation strategy to study combined treatment approaches in vivo 
with the perspective to translate the results from bench to bedside. 
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Introduction 
Colorectal cancer (CRC) is the third most common cancer worldwide and ranked fourth in 
cancer mortality. It shows higher incidence rates in developed countries and in the male 
population [1]. CRC cells metastasize to different organs. Caused by the portal circulation, the 
liver is the most frequent organ acquiring colorectal metastases (CLM) and accounts for 70 % 
of the metastatic lesions in CRC patients [2]. Surgical resection is the most effective treatment 
option for colorectal liver metastases, but depending on location, size and number of 
metastases, only a minority of patients are eligible for surgery [3, 4]. Metastases that cannot 
be surgically resected are treated with systemic or local chemotherapy and if possible with 
radiofrequency ablation (RFA) [5, 6]. However, the success of these therapies often remains 
insufficient [7, 8]. Conventional radiotherapy of hepatic tumor lesions has only played a very 
limited role, as radiotoxicity in the non-tumorous liver tissue often leads to radiation-induced 
liver disease (RILD) [9]. However, with the development of stereotactic body radiation therapy 
(SBRT) it is nowadays possible to precisely deliver conformal high doses of ionizing radiation 
(IR) to the tumor without overly compromising the healthy surrounding tissue [10]. A 
prospective phase II clinical trial, investigating SBRT of patients with inoperable colorectal liver 
metastases demonstrated optimal local control and promising overall survival rates without 
causing RILD or other severe radiation-induced complications [11]. To further understand and 
improve SBRT of colorectal liver metastases, preclinical animal models that accurately 
represent the clinical situation have to be investigated. Numerous rodent models wherein 
cancer cells are injected to the cecal wall and thereby resemble primary colorectal tumors in 
patients have been described. Unfortunately, only few of the models succeed to specifically 
metastasize to the liver or have an unpractically low penetrance rate and long incubation time 
[12, 13]. Other routes of CRC cell injections include the spleen, portal vein or the hepatic 
parenchyma [14-16]. As opposed to intrasplenic or hepatic injection, the portal route mimics 
vascular spread and limits the risk of tumor growth at other intra-abdominal organs than the 
liver [17]. In recent years, the field of small-animal image-guided radiotherapy has made 
tremendous progress. CT-based treatment planning with Monte Carlo dose calculation, 
followed by static or dynamic irradiation enables to precisely treat very small structures in 
animal models [18]. 
In this study, we generated an animal model to study the orthotopic irradiation of colorectal 
liver metastases with SBRT. Contrast-enhanced cone beam CT (CBCT) and histological 
characterization of IR-induced cellular damage were employed to achieve an optimal balance 
between tumor targeting and sparing of surrounding healthy organs. To follow volumetric 
changes in colorectal liver metastases after SBRT, we used MRI. 
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Material and Methods 
Cell culture 
The murine colorectal cancer cell line MC-38, a kind gift from Prof. B. Becher (Institute of 
Experimental Immunology, University of Zürich), was cultured in DMEM cell culture medium 
supplemented with L-glutamine (GlutaMAX, Life Technologies), 10% FBS and 1% penicillin-
streptomycin at 37°C in 5% CO2. MC-38 cells have been tested negative for mycoplasma 
(Mycoplasma Detection Kit, Lonza). Cell number and cell viability were determined using an 
automated cell counter (NucleoCounter® NC-200 TM, Chemometec). 
Orthotopic colorectal liver metastases model 
MC-38 cells were orthotopically transplanted to the liver of 8-week old, female C57BL/6 mice
(Envigo). The surgical protocol was adapted from Limani et al. [19]. Before laparatomy,
Buprenorphine (0.1 mg/kg, subcutaneous) was preoperatively administered and anesthesia
was induced by isoflurane inhalation. The caudate liver lobe was detached from ligaments and
completely resected and a microvascular clamp was applied to the portal triad, supplying the
left and median liver lobes. For injection, exponentially growing MC-38 cells (2 x 105 cells/100
µL PBS) were injected in the portal vein (29G needle). Hemorrhagic control was performed
using TachoSil and by compression with cotton swabs. The clamp was removed and the
abdominal walls were closed by sutures. After surgery, animals were allowed to recover on a
warming pad in a separate cage until completely conscious. For pain relief, buprenorphine was
injected after surgery every 3-6 hours. All animals were maintained under specific pathogen-
free conditions. All experiments were performed in accordance with Swiss Federal Animal
Regulations and approved by the Veterinary Office of Zurich.
Image-guided radiotherapy 
An image-guided small animal radiotherapy platform (Precision X-Ray, X-Rad SmART) 225 
kV unit with a dose rate of 3 Gy/min, equipped with a cone beam CT (CBCT) scanner was 
used for mouse irradiation. Animals were kept under isoflurane anesthesia for imaging and 
irradiation. Fenestra LC or Fenestra VC (MediLumine TM) contrast-enhancing agent, 
specifically taken up by hepatocytes, was intraperitoneally (LC) or intravenously (VC) injected 
at a concentration of 8 ml/kg at least 2 hours prior to CBCT-imaging. 
Blood serum analysis 
Serum albumin, bilirubin, alanine aminotransferase (ALT) and aspartate aminotransferase 
(AST) levels were measured with a multiple biochemical analyzer (Fudji Dri-Chem 4000i).  
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MRI 
MRI was conducted on a 4.7 T/16 cm Bruker PharmaScan small animal scanner (Bruker 
BioSpin) equipped with a transmit/receive 40 mm bird-cage resonator. After anatomical 
reference images were obtained in coronal, transversal and sagittal slice orientations (FLASH 
sequence, TR/TE 200/3 ms, image matrix size 128 x 128, FOV 60 x 60 mm2, 5 slices) T2-
weighted images were collected with a fat-suppressed RARE sequence (TEeff/TR 22/2950 
ms, NA 4, RARE Factor 4, matrix size 256 x 256, FOV 30 x 30 mm2) from 40 axial slices at a 
spatial resolution of 117x117x500 µm3. During MRI, mice were placed in supine position onto 
a heated animal bed and maintained under isoflurane anesthesia. Image analysis was 
performed with the OsiriX DICOM viewer. 
Immunohistochemistry 
Immunohistological endpoints were analyzed on formalin-fixed paraffin-embedded (FFPE) 3 
µm tissue sections for hematoxyline & eosine (H&E) and γH2AX (1:1000, Cell Signaling, 
20E3). Images were taken on a wide-field Nikon Eclipse TI microscope. 
Statistical analysis 
The effects of IR on relative animal weight and colorectal liver metastases volume changes 
were analyzed by one-way ANOVA with Tukey post test. For the analysis of serum markers, 
values were first tested for normal distribution by the Shapiro-Wilk test and subsequently 
compared by t-test or Mann-Whitney test. Statistical analyses were performed using GraphPad 
Prism v7. 
Results 
Portal vein injection is a powerful tool to study colorectal liver metastases 
MC-38 cells were orthotopically transplanted to the liver of female C57BL/6 mice via the portal
vein. In 90% of the operated mice, colorectal liver metastases developed successfully in the
right liver lobe. H&E staining could differentiate colorectal liver metastases from the healthy
hepatic tissue (Fig. 1E). The most frequent complication was hemorrhagic bleeding after
intraportal cell injection caused by increased portal pressure after clamping of the portal vein
and removal of the caudate liver lobe. Portal bleeding provoked intraperitoneal carcinomatosis
and approximately 10 % of the mice died after surgery.
Abdominal organs have approximately the same tissue density and discrimination of the liver
from other organs by conventional CT-imaging is hampered (Fig. 2A). To overcome this
challenge, two different liver-specific contrast agents were tested (Fenestra LC & VC).
Intraperitoneal administration of the LC contrast agent distincted the liver from its surrounding
organs already 80 minutes after injection (Fig. 2B) and remained active for up to 7 hours after
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injection (Fig. 2C). The VC contrast agent was equally potent in distinguishing the liver from 
other organs at 7 hours after injection but was not active at 80 minutes after administration 
(data not shown). In addition, both contrast agents showed unspecific uptake in the spleen. 
Since these contrast agents are only taken up by hepatocytes and not colorectal tumor-derived 
carcinoma cells, metastatic nodules should be distinguishable from the healthy liver. However, 
presumably caused by the low resolution of the CT scans, could not detect colorectal liver 
metastases in the tumor-bearing liver lobe. In some liver scans, we observed structures without 
contrast-enhancement but we could not reliably determine whether these are colorectal liver 
metastases or parts of the small intestine. 
Overall, these results demonstrate that the contrast of the liver can be enhanced by Fenestra 
contrast agents in a time-dependent manner and thereby facilitate treatment planning. (Due to 
the favorable pharmacokinetics, we decided to perform the following experiments with the 
Fenestra LC contrast agent). 
The right liver lobe can be targeted with acceptable healthy tissue involvement 
In order to define a treatment plan with maximal tumor coverage and minimal normal tissue 
toxicity different irradiation approaches were designed. The entire tumor-bearing liver lobe was 
planned for irradiation, since single metastases were not accurately detectable by contrast-
enhanced CT-imaging. Due to the lack of a multileaf collimator and the inability to control for 
breathing-related liver movements irradiation of the tumor-bearing liver lobe was performed 
with a rectangular collimator (8 x 12 mm). 
Dose-volume histograms (DVHs) of different irradiation plans were calculated for the tumor-
bearing liver lobe and the relevant organs at risk, which included the healthy liver, the right 
kidney and the stomach. The small intestine and the colon could not be included in the 
calculations, as their clear differentiation on a CT scan is impossible (Fig. 3A).  
Maximal tumor coverage was achieved when two opposing beams (AP/PA) were planned. The 
directly adjacent right kidney thereby receives approximately the same dose as the tumor-
bearing liver lobe. As this lobe corresponds to only approximately 20 % of the whole liver, the 
dose to the remaining healthy liver was relatively low. The angle of the two opposing beams 
could be positioned in a way to almost completely spare the stomach from ionizing radiation 
(Fig. 3B). More complex irradiation plans e.g. arc-beam therapy, wherein the respective liver 
lobe is targeted with a 360°-rotating radiation beam were inferior. In such a protocol, the 
median dose to the tumor was reduced by approximately 1.2 fold but at the same time the 
median dose to the healthy liver and to the stomach were strongly increased (9 and 20 fold, 
respectively). On the other hand, arc beam therapy favored the dose deposition to the kidney, 
by delivering a 1.4 fold lower dose. 
Therefore, the AP/PA irradiation approach was used for tumor irradiation compromising best 
tumor coverage and healthy tissue sparing. 
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The in silico treatment plan successfully translates to the biological readout of DNA 
damage 
In a test cohort of healthy mice, different liver segments were histologically analyzed one hour 
after irradiation for IR-induced γH2AX-foci formation as a marker for IR-induced DNA double 
strand breaks. Dense staining of γH2AX-foci was detectable in the right liver lobe (Fig. 4C). 
Staining intensity of γH2AX-foci in other liver segments further decreased proportionally to the 
distance from the treatment planning volume, e.g. an intermediately-intense staining was 
detectable in the middle liver lobe, which is anatomically in close proximity to the right lobe, 
whereas the left liver lobe was free from γH2AX-foci (Fig. 4A, B). Thereby, we demonstrated 
that we could precisely deliver ionizing radiation and its accompanying DNA damaging 
potential towards colorectal liver metastases.  
Irradiation of the right liver lobe with doses above 20 Gy is hepatotoxic 
In order to determine the maximally tolerated dose of IR and potential late-phase toxicities, 
e.g. RILD, the right liver in a cohort of metastases-free, healthy mice was irradiated with single
fractions of either 0, 20 or 30 Gy. As a potent surrogate marker for animal well-being, body
weights were regularly monitored after irradiation. While sham-irradiated mice gained in body
weight, body weight drastically decreased in mice irradiated with a single dose of 20 or 30 Gy
(0 Gy vs. 20 Gy: p= 0.003, 0 Gy vs. 30 Gy: p= 0.0006) (Fig. 5A). Furthermore, two out of four
mice irradiated with 30 Gy were found dead at 44 and 48 days after irradiation respectively.
To investigate liver functional parameters, the serum concentrations of alanine transaminase
(ALT), aspartate transaminase (AST), bilirubin and albumin was determined in mice 50 days
after irradiation. As compared to sham-irradiated mice, the AST levels were 2.5-fold (p= 0.01)
and the ALT levels 1.3-fold (p= 0.11) increased in mice irradiated with 20 Gy, indicating hepatic
inflammation (Fig. 5B, C). Whereas bilirubin levels were not affected, the concentration of
serum albumin was 2-fold (p= 0.002) decreased after irradiation with 20 Gy (Fig. 5D, E). As
albumin is produced and secreted by the liver, these results indicate liver impairment. Since
only two mice remained in the group irradiated with 30 Gy at this time point, their values were
excluded for the analysis. Overall, irradiation of the right liver lobe with s single fraction equal
or higher than 20 Gy is hepatotoxic and potentially lethal for the female C57bl6 mouse model
(see discussion below).
IR dose-dependently reduces the growth of colorectal liver metastases 
An IR-dose-response tumor growth delay experiment was performed in metastases-bearing 
mice. Metastases could be detected in the right liver lobe by MRI 14 days after surgical 
implantation. At day 15, the right liver lobe of mice was irradiated with increasing single doses 
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from 0 to 15 Gy. Once weekly, the mice were scanned by MRI to monitor the cumulative 
change in tumor volume after irradiation (Fig. 6A). As determined by relative weight change, 
all doses were well tolerated throughout the course of the experiment (Fig. 6B). Irradiation of 
the right liver lobe successfully reduced the growth of colorectal liver metastases in a dose-
dependent manner. While the cumulative metastasis-volume of unirradiated mice increased 
by 22-fold within 2 weeks, irradiation with 10 Gy increased the volume only by 4-fold (p= 0.05). 
Furthermore, irradiation with a single fraction of 15 Gy even decreased the volume by 1.2-fold 
(p= 0.02) at the same time point (Fig. 6C, D). 
Overall, our results demonstrate that stereotactic irradiation of colorectal liver metastases is 
feasible and effective also on the preclinical level. This approach enables to study combined 
treatment modalities against CLMs in vivo, to further decrease the radiation dose delivered to 
the radiosensitive liver thereby reducing normal tissue toxicities.  
Discussion 
Stereotactic radiotherapy is an emerging approach for the treatment of patients suffering from 
non-resectable colorectal liver metastases. Although it is already being investigated in clinical 
routine for over a decade, to our best understanding no studies have been performed on the 
preclinical level. Up to now, targeted irradiation to orthotopic CLMs in rodents was only applied 
by brachytherapy [20]. Owing to fundamental progress in small-animal image-guided 
radiotherapy, it is nowadays adequate to translate preclinical SBRT results into clinical 
practice.  
In this study, we present a highly reproducible mouse model to study SBRT of CLMs. The liver 
is a comparably radiosensitive organ and application of high IR-doses often leads to RILD [21]. 
Our model restricts CLM formation to the right liver lobe, which enables selective ablation of a 
small liver fraction (approximately 20 % of the total liver) and thereby decreases hepatotoxicity 
in the remaining healthy liver. In addition, removal of the caudate liver lobe prevents co-
irradiation of the stomach, which is anatomically covering the caudate liver lobe. Contrast-
enhanced CT imaging, clearly delineating the metastatic liver lobe, further reduced 
unnecessary involvement of healthy liver tissue. Furthermore, it strongly facilitated the 
recognition of other abdominal organs and allowed to generate a DVH of the relevant organs 
at risk. We ascertained selective liver lobe irradiation by Monte-Carlo based dose calculations 
and by immunohistochemical analyisis of DNA DSBs in different liver lobes. 
Wu et al. aimed to define the exact doses that result in hepatotoxicity in healthy mice and 
observed significant changes in RILD parameters when the whole liver was irradiated with 
single fractions of 25 Gy or higher [22]. Based on these results we designed a dose-escalation 
study in our CLM model. Interestingly and considering that we only irradiated 20 % of the liver, 
significant weight loss and RILD signs were already determined at single doses of 20 Gy. This 
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discrepancy in radiation tolerance could be due to several reasons. RILD is a time-dependent 
phenomenon, and whereas Wu et al. assessed RILD parameters at 3 weeks after irradiation, 
we sacrificed the irradiated mice after 7 weeks. Furthermore, their experiments were 
performed in male mice, while our mice had another genetic background and were female. 
Other researchers demonstrated that female mice are more sensitive to liver irradiation [23]. 
Most importantly, we cannot exclude the involvement of other abdominal organs to the 
observed toxicity. As compared to the study of Wu et al., our irradiation approach delivered a 
substantially higher dose to the right kidney. Contribution of renal radiotoxicity to animal weight 
loss is however rather unlikely, as Ahmad et al. have shown that even bilateral kidney 
irradiation with a total dose of 14 Gy is not lethal for the course of at least 11 weeks [24]. Even 
though we did not observe any of the typical signs for gastrointestinal radiotoxicity, including 
pain, diarrhea and rectal bleeding, we cannot entirely exclude an involvement between healthy 
tissue toxicity of the small intestine and the extended body weight loss after irradiation with 20 
and 30 Gy, respectively [25].  
Single fractions of 15 Gy were well tolerated and sufficiently high to induce a cytostatic effect 
in CLMs. We demonstrated significant delay in tumor growth upon right liver lobe irradiation 
with single fractions of 10 or 15 Gy. Nonetheless, it will be of high importance to increase the 
maximally tolerated dose of IR towards the liver, since CLMs contain larger proportions of 
radioresistant hypoxic cells compared to other tumor types [26]. In addition, combined 
treatment modalities with hypoxia-targeting or immunomodulating compounds might even 
further extend the therapeutic window. 
Here, we deliver a robust and reproducible preclinical CLM model and irradiation strategy to 
study such combined approaches with the perspective to translate the results from bench to 
bedside. 
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Figure Legends 
 
Fig.1 Surgical approach for the selective intraportal injection of colorectal cancer cells. (A) 
Schematic representation of a healthy murine liver prior to surgery. (B) The caudate liver lobe 
is surgically removed. (C) The portal vein is clamped above the right liver lobe and colorectal 
cancer cells are injected in the portal vein, resulting in metastases specifically in the right liver 
lobe. (D) The irradiation field is restricted to the right liver lobe with a rectangular collimator (E) 
H&E staining showing the border between a colorectal liver metastasis and the healthy liver. 
Fig.2  Abdominal CT scans of a mouse with colorectal liver metastases. (A) CT scan without 
contrast enhancement. (B) CT scan at 80 minutes after intraperitoneal injection of the Fenestra 
LC contrast agent. (C) CT scan at 7 hours after intraperitoneal injection of the Fenestra LC 
contrast agent. 
Fig.3 Treatment plan for the irradiation of colorectal liver metastases. (A) Contrast-enhanced 
CT scan with delineation of the target volume (cancerous liver) and organs at risk (total liver, 
healthy liver, right kidney and stomach). (B) Dose volume histogram of an AP/PA treatment 
plan. (C) Dose volume histogram of a 360° arc-beam treatment plan. 
Fig.4 Histological characterization of DNA double strand breaks by γH2AX staining 1 hour after 
irradiation with 10 Gy. Staining was performed for the (A) middle (B) left and (C) right liver lobe. 
(D) Unirradiatet right liver lobe with colorectal liver metastasis as control. 
Fig.5 Evaluation of radiation-induced toxicity after single fraction irradiation of the right liver 
lobe of healthy mice with 0, 20 or 30 Gy. (A) Relative weight change monitored for 6 weeks 
after radiotherapy. Dotted line = 0 Gy, full line = 20 Gy, dashed line = 30 Gy. Serum 
concentrations at 50 days after radiotherapy for (B) aspartate transaminase (C) alanine 
transaminase (D) bilirubin and (E) albumin. 
Fig.6 Irradiation of mice with colorectal liver metastases with increasing single doses of IR. (A) 
Treatment schedule for surgery, irradiation and imaging of the mice. (B) Relative weight 
change at one and two weeks after irradiation. (C) Representative abdominal MRI scans at 
one day before and two weeks after irradiation with 0 and 10 Gy, respectively. (D) Dose-
dependent change in relative, cumulative metastatic volume at one and two weeks after 
radiotherapy. 
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4. Discussion 
4.1 Current status of hypoxia modulation for radiotherapy 
Tumor hypoxia occurs in almost all solid tumor entities [170]. On the one hand, hypoxia renders 
most solid tumors partly resistant to radiotherapy but on the other hand represents itself as 
promising target to overcome radioresistance. As such, an ideal radiosensitizer targeting tumor 
hypoxia should work independently of the genetic background and protein expression pattern of 
the respective cancer cells. The mechanisms and molecular aberrations leading to hypoxia in solid 
tumors are nowadays well known.  In response to low oxygen concentrations, HIF-1α is stabilized 
in cancer cells and translocates to the nucleus where it promotes the expression of target genes 
that aim to restore the oxygen levels in the affected hypoxic cells [49]. Owing to the high 
proliferation rate of cancer cells, the cellular oxygen restoration process is usually unsuccessful in 
solid tumors. In fact, overproduction of VEGF results in a leaky and chaotic tumor vasculature and 
promotes a vicious cycle of angiogenesis and hypoxia [205]. The molecular hypoxia response 
process offers a handful of druggable targets that may prevent hypoxia progression and its 
associated negative consequences. As previously discussed in the introduction of my thesis, 
selective HIF-1α inhibition was associated with toxicity and did not result in therapeutic efficacy. It 
is important to note that HIF-1α inhibition increases the expression of the compensatory subunit 
HIF-2α and results in a more aggressive and invasive tumor phenotype [206]. Moreover, the exact 
function and relation of the third subunit HIF-3α, which was found to be a negative regulator of 
HIF-1α and HIF-2α remains to be fully elucidated [207]. Therapeutic efficacy of HIF-inhibition may 
be enhanced by developing inhibitors selectively targeting HIF-2α or both HIF-α subtypes 
simultaneously and by unravelling the role of HIF-3α. 
Recent attempts to target the hypoxia response pathway have focussed on the tumor metabolism. 
Cancer cells reprogram their metabolism from oxidative phosphorylation to glycolysis in response 
to HIF-1α expression. Glycolysis and increased expression of the glucose transporter GLUT-1 - as 
detected in various tumor entities - is associated with radioresistance [208-211]. Molecular 
targeting of GLUT-1 and its downstream effectors may represent an effective way to improve the 
outcome of radiotherapy [212]. Selective GLUT-1 inhibitors have recently been developed and 
tested in preclinical tumor animal models in combination with radiotherapy. The GLUT-1 inhibitor 
WZB117 sensitizes radioresistant breast cancer cells to radiotherapy and novel compounds with 
improved selectivity against other GLUT isoforms e.g. BAY-876 are currently being tested on the 
preclinical level [213, 214]. 
As mentioned earlier, an ideal radiosensitzer should be active in a wide variety of tumor entities, 
independent of deregulated signalling pathways. Therefore, multitudes of pharmaceutical agents 
targeting the physiological consequences of tumor hypoxia have been developed in the past 
decades. Some of the treatment regimens including Carbogen and nitroimidazoles were briefly 
described in the introduction. Although Carbogen treatment slightly improves the outcome of 
radiotherapy, the practical limitations accompanying its use result in minimal clinical impact [215]. 
Metronidazole and Misonidazole were associated with frequent side effects and lack of efficacy. 
They were replaced with third generation nitroimidazoles like Etanidazole and Nimorazole, which 
were expected to yield a more potent radiosensitization together with decreased toxicity [195, 
216]. Jens Overgaard summarized the clinical significance of hypoxia modifiers for radiotherapy 
(Carbogen & nitroimidazoles) in a meta-analysis reviewing 4805 HNSCC patients treated in 32 
randomized clinical trials. Unfortunately, hypoxia modifications did not result in significant 
benefits in both loco-regional control and survival. Nevertheless, two individual trials showed a 
significant improvement in loco-regional control. Interestingly, these two studies investigating 
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Misonidazole and Nimorazole were among the few trials with a sufficiently large number of 
patients, indicating the importance of patient selection and cohort size for statistical power [217]. 
The aim of this PhD thesis is to overcome radioresistance by targeting tumor hypoxia with novel 
pharmacological approaches. As such, we have investigated two different classes of anti-hypoxia 
compounds exploiting the physiological abnormalities associated with tumor hypoxia. The first 
approach involved a hypoxia-activated prodrug that selectively kills hypoxic tumor cells, while in 
the second approach we restored the oxygen levels in hypoxic cells. 
Figure 8 Tumor hypoxia is a major factor contributing to radioresistance. Hypoxia especially limits the 
efficacy of hypofractionated irradiation as it does not exploit the process of tumor reoxygenation that partly 
occurs between single IR-fractions in fractionated radiotherapy. The aim of this PhD thesis is to overcome 
hypoxia-mediated radioresistance by distinct pharmacological approaches. On the one hand we have 
investigated the effect of the hypoxia-activated prodrug evofosfamide that selectively kills hypoxic tumor 
cells and on the other hand we restored the hypoxic tumor fraction with myo-inostiol trispyrophosphate 
(ITPP). We demonstrate that both compounds act synergistically with high-dose radiotherapy and 
significantly delay the growth of tumors when compared to high-dose radiotherapy alone. 
4.2 Hypoxia activated prodrugs and their implications in clinical 
oncology 
Hypoxia-activated prodrugs are specifically activated under low oxygen concentrations to their 
active, DNA-alkylating state. The rationale behind HAPs was to develop compounds that act 
independently of the genetic tumor background and solely rely on hypoxia for their activation. 
However, recent preclinical investigations however revealed that also expression of prodrug-
activating oxidoreductases and intrinsic sensitivity of cancer cells to the cytotoxic effector 
determine the efficacy of HAPs [218].  
In this PhD project, we evaluated the radiosensitizing potential of evofosfamide (Th-302) with 
fractionated and hypofractionated radiotherapy. We identified a synergistic effect of evofosfamide 
in combination with radiotherapy in a NSCLC model, while evofosfamide on its own was inactive 
in a HNSCC model. Interestingly, both tumor models were hypoxic to the same extent as 
determined by pimonidazole staining, thereby eliminating physiological hypoxia levels as 
resistance mechanism. Using genome-scale shRNA screens, Hunter at al. have previously identified 
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the P450 Oxidoreductase (POR) as a major determinant of sensitivity to HAPs in vitro [219]. We 
demonstrated high expression of POR in the evofosfamide-responding NSCLC tumor xenografts, 
whereas the resistant HNSCC tumors were found to be negative for POR expression by 
immunohistochemistry. SiRNA-mediated knockdown of POR in the responding NSCLC cell line 
completely abrogated the activity of evofosfamide in vitro. Considering the recent failure of two 
clinical trials with the preclinically potent HAPs tirapazamine and evofosfamide it will be important 
to include predictive biomarkers of HAP-activity to select patients [200, 220]. 
Assessment of tumor hypoxia would be a straightforward approach to select for patients expected 
to benefit from HAP treatment. A retrospective analysis of HNSCC patients treated with 
radiotherapy and either tirapazamine or cisplatin/5-FU revealed that patients with baseline tumor 
hypoxia had improved loco-regional control and failure free survival upon tirapazamine treatment 
[221]. Despite these clinical observations, the baseline tumor hypoxia was not determined in 
patients selected for the evofosfamide trial, but instead respective treatment groups were assigned 
randomly. As such, therapeutic failure of evofosfamide as compared to doxorubicin in patients 
suffering from soft tissue sarcoma has to be regarded carefully. Soft tissue sarcomas are not 
amongst the most hypoxic tumor entities and the distribution of tumor hypoxia across different 
patients is relatively high [222, 223]. Moreover, patients were not screened for POR expression 
prior to treatment. Definition of predictive biomarkers for HAP activity (e.g. Hypoxia or POR 
expression) and their incorporation into patient stratification will be of high importance for the 
success of future clinical trials. An effective but invasive solution would be histological staining of 
tumor biopsies for POR expression and a hypoxia marker, e.g. CAIX. Unfortunately, based on the 
negative outcome of evofosfamide in the pivotal phase III clinical trial its registration and other 
ongoing clinical trials were discontinued without considering the lack of patient selection. A 
number of novel HAPs with higher potency are currently being tested in preclinical trials [224-
227]. To translate the increased potency of these compounds into improved tumor control in 
patients, it will be crucial to include predictive patient selection criteria. 
4.3 Overcoming radioresistance by tumor reoxygenation with myo-
inositol trispyrophosphate 
In this PhD project, we demonstrate that neoadjuvant myo-inositol trispyrophosphate (ITPP) 
administration synergistically enhances the cytotoxic effect of ionizing radiation. Pharmacokinetic 
monitoring of tumor reoxygenation with a non-invasive luciferase-based hypoxia reporter 
construct revealed rapid tumor reoxygenation already 2 hours after ITPP injection. Tumor oxygen 
levels steadily decrease to the baseline level over a course of 24 hours post ITPP administration. 
Given these aspects, it is crucial to synchronize the irradiation time with the maximal tumor 
oxygenation state, which is reached 2 hours after intraperitoneal ITPP injection. Furthermore, the 
synergistic radiosensitization is dependent on the injected dose of ITPP. The maximal tolerated 
dose (MTD) was determined as an intraperitoneal bolus of 3 g/kg. Doses of 1.5 g/kg and lower 
failed to induce tumor reoxygenation and consequently did not result in radiosensitization as 
determined by tumor growth delay experiments. Doses of 4 g/kg and higher were associated with 
acute toxicities that resulted in sudden death in approximately 20 % of the mice. Post mortem 
examinations by experienced veterinarians could not determine the exact cause of death. 
Considering the molecular structure of ITPP that contains six sodium ions per molecule (myo-
inositol trispyrophosphate hexasodium salt) and additionally requires 0.04 equimolar sodium 
hydroxide for pH neutralization, the observed acute toxicities are presumably caused by 
hypernatremia. This hypothesis is further supported by the apathetic behaviour and thirst of 
animals immediately after injection, both associated with hypernatremia in humans [228]. Since 
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the lower doses of 3 g/kg did not result in toxicities and at the same time substantially induced 
tumor reoxygenation we did not investigate the described side effects. 
The exact mechanism by which ITPP leads to tumor reoxygenation is yet to be elucidated. It was 
shown that ITPP is actively taken up by erythrocytes via the anion transporter band3 [203]. The 
according implications are unclear but it is hypothesized that ITPP influx lowers the intracellular 
pH in erythrocytes, thereby decreasing the binding affinity between hemoglobin and oxygen. 
Consequently, oxygen liberation from hemoglobin facilitated oxygenation of tissues upon 
demand. Oxygen is unevenly distributed in tissues, forming pO2 gradients along the small blood 
capillaries from the arterial to the venous ends [42]. The physiological oxygen levels in the human 
body are regulated by an equilibrium between oxygen availability and oxygen demand and range 
between 110 mmHg in lung alveolar cells to 8 mmHg in superficial skin cells [229]. Increased 
oxygen availability upon ITPP treatment is unlikely to hyperoxygenate tissues with a physiological 
pO2 but will rather instantaneously reoxygenate tissues residing in a hypoxic state, e.g. solid 
tumors. Raykov et al. could confirm this hypothesis by invasively measuring pO2 levels of pancreatic 
carcinoma xenografts and healthy muscle upon ITPP injection. ITPP drastically reoxygenated the 
hypoxic tumor xenografts whereas the physiological pO2 in the muscle was not increased [41]. 
As such, ITPP does not directly act on cancer cells but rather indirectly affects their tumor 
microenvironment. We could confirm this fact by demonstrating a lack of radiosensitization in cell 
culture experiments. By targeting hemoglobin, ITPP is capable of reoxygenating hypoxic tumors 
irrespectively of their anatomic and genetic background. Therefore, the radiosensitization is 
dependent on the physicochemical extent of reoxygenation. We could demonstrate that the 
synergistic effect of ITPP and IR was higher in a tumor model with a high hypoxic fraction (A549 
NSCLC) as compared to a tumor model with a low hypoxic fraction (FaDu HNSCC). Apart from 
rapidly induced physicochemical tumor reoxygenation, we further identified a protective effect of 
ITPP on the tumor microvasculature. High-dose fractions of IR lead to endothelial cell death and 
subsequent reduction of the tumor micro vessel density as reported by other groups [230]. 
Neoadjuvant ITPP administration however completely abrogates IR-mediated vascular depletion. 
Our in vitro data shows increased PTEN and decreased pAKT levels in cancer cell lysates and 
HUVEC endothelial cells upon ITPP treatment. In line with our results, Kieda et al. could 
demonstrate PTEN activation specifically in tumor endothelial cells after ITPP treatment [231]. 
Activation of PTEN in endothelial cells could promote a radioprotective effect in the vasculature, 
since it was recently demonstrated that stromal PTEN loss is associated with decreased DNA repair 
and genomic instability in the associated epithelium [232]. Further evidence for radioprotection 
could be observed in our orthotopic colorectal liver metastases mouse model. Ablation of the right 
liver lobe of healthy mice with a single IR fraction of 20 Gy resulted in a profound weight loss and 
irradiation with 30 Gy was even lethal for 50 % of the animals tested. In agreement with this 
deteriorating progression, blood serum analysis indicated an impaired liver function 7 weeks after 
irradiation, as determined by increased AST and decreased serum albumin levels. Neoadjuvant 
ITPP administration remarkably diminished the radiation-induced weight loss and none of the 
irradiated animals died over the course of the experiment. As these mice had no tumors, ITPP 
exerted its effect on the healthy liver tissue.  
We confirmed that increased IR-induced DNA damage following tumor reoxygenation is the 
underlying mechanism of the synergistic effect of ITPP and IR. Neoadjuvant ITPP treatment 
selectively increased the number of DNA DSBs in initially hypoxic tumor areas and did not elevate 
the amount of DNA damage in the normoxic tumor regions. This further supports the hypothesis 
of selective radiosensitization of hypoxic tissues and inactivity in tissues with a physiological pO2. 
Further experiments will be necessary to unravel the promising role of ITPP on radioprotection of 
healthy tissue. 
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Additional experiments investigating the effect of multimodal ITPP and IR treatment in 
immunocompetent mice bearing MC-38 colorectal carcinoma allografts determined a secondary 
effect of ITPP. Even though these tumors only manifest with intermediate tumor hypoxia, they 
had the strongest growth delay upon combined ITPP and IR treatment amongst all evaluated 
tumor models. We could confirm that the radioprotection in the tumor vasculature was 
accompanied with improved immune cell infiltration. The emerging use of SBRT relies on distinct 
radiobiological features compared to classical fractionated radiotherapy, including enhanced 
release of tumor antigens and vascular depletion [139]. Depletion of the tumor vasculature is 
mutually regarded as a positive asset of SBRT as it indirectly induces cell death by starving tumors 
from nutrients [230, 233]. However, thoracic and abdominal SBRT is often associated with 
toxicities, especially when combined with anti-VEGF therapy [234-236]. A combined treatment 
modality of ITPP and SBRT could prevent vascular depletion while maintaining enhanced tumor 
antigen secretion. Thereby activated immune cells could augment tumor control by improved 
accessibility of cancer cells to the intact tumor vasculature. Preservation of the tumor vasculature 
would consequently impede tumor hypoxia and its associated malignant transformations resulting 
in treatment resistance. 
In conclusion, we demonstrate that ITPP sensitizes hypoxic tumors to radiotherapy, irrespective of 
their anatomic and genetic background. Selective sensitization of hypoxic tissues manifests in low 
off-target toxicity and even poses the hypothesis of radioprotection by presently unclear 
mechanisms. Our results provide a strong rationale to evaluate the clinical efficacy of neoadjuvant 
ITPP treatment combined with SBRT in clinical trials. 
4.4 Implementation of image-guided small animal radiotherapy in 
Zurich 
Radiotherapy is a fundamental treatment approach to combat cancer. Unlike in the field of 
chemotherapy or immunotherapy, the translation of data obtained from preclinical radiotherapy 
studies to the clinical setting is aggravated by the lack of clinically comparable beam-delivery 
platforms. To bridge the gap between preclinical and clinical radiotherapy, we implemented an 
image-guided small animal radiotherapy platform in this PhD project. 
Historically, targeted tumor irradiation in small animals was achieved by shielding the healthy 
tissue with lead and exposing the tissue to be irradiated to the photon beam. Nowadays, CT-
based treatment planning together with dynamic beam-delivery systems allow us to apply clinically 
relevant irradiation protocols to small animals. To further investigate our promising results 
obtained with ITPP treatment of subcutaneous tumors, we generated an orthotopic colorectal 
liver metastases (CLM) model. CLMs manifest in a high unmet need for novel treatment strategies, 
as the golden standard - surgical resection - is not always applicable [237]. A recent phase II clinical 
trial demonstrated optimal local control and promising overall survival rates in CLM patients 
treated with SBRT [238]. The rationale for combining ITPP and SBRT for this indication is given by 
the high hypoxic fractions found in CLMs [239-241]. Moreover, our collaborators could 
demonstrate a combined effect of ITPP and chemotherapy in the same CLM model [242, 243].  
Our own results demonstrate the feasibility of highly selective irradiation of the right liver lobe 
with acceptable healthy tissue involvement. In contrast to the results obtained by Wu et al. after 
total liver irradiation, we observed signs of hepatotoxicity at lower doses despite irradiating only 
a fifth of the liver volume [244]. The presumably reasons for this observation, including differences 
in tissue sampling, mouse model and gender were adequately discussed in our manuscript. 
Nonetheless, CLM irradiation with single doses of 15 Gy and lower was well tolerated and resulted 
in dose-dependent tumor growth kinetics. Preliminary multimodal treatments with ITPP indicated 
a radioprotective effect on the healthy liver as previously discussed. Moreover, a pronounced 
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tumor reoxygenation occurred in orthotopic CLMs after ITPP treatment as determined by 
pimonidazole staining. In the next step, we will assess the combined treatment of ITPP and image-
guided radiotherapy in orthotopic CLMs. 
In conclusion and to our best knowledge, we could show for the first time that small animal 
image-guided radiotherapy of CLMs is feasible, accurate and effective. Even though we observed 
a tumor growth arrest at two weeks after a single fraction of 15 Gy, further radiosensitization will 
be necessary to ameliorate tumor control over a longer period and to translate novel treatment 
protocols to the clinical stage. 
4.5 Translational relevance 
The major goal of this PhD project was to investigate novel treatment strategies to overcome 
radioresistance in cancer patients. Tumor hypoxia is a highly complex phenomenon driven by a 
dysregulated tumor microenvironment including the vasculature, tumor stroma and immune cells. 
As such, in vivo experiments were crucial to simultaneously incorporate all contributing factors 
associated with tumor hypoxia in order to generate clinically relevant data. 
Our results demonstrate that evofosfamide is a potent radiosensitizer for hypoxic cancer cells 
expressing POR. Other groups observing synergistic effects in different tumor entities support our 
findings [245, 246]. Nevertheless, the registrational clinical trial investigating evofosfamide in soft 
tissue sarcoma patients failed due to inefficacy [200]. Inadequately translational preclinical tumor 
animal models and major differences between murine and human carcinogenesis are often used 
to explain clinical failure of novel compounds. However, in this case it is legitimate to question the 
design of the clinical trial. Redundant results from Hunter et al. and our group strongly support 
the importance of POR expression for the bioreductive activation of evofosfamide [219]. Based on 
these findings, the lack of patient stratification according to tumor hypoxia and POR-expression is 
likely to be the reason for the failure of this phase III clinical trial. Discontinuation of other clinical 
trials involving evofosfamide without regarding the aspect of patient stratification scrutinizes the 
attempts of preclinical researchers to conduct translational research by identifying biomarkers 
predictive for treatment outcome [198]. 
Resistance to novel anti-cancer compounds is frequently caused by selection of pre-existing cancer 
cells that are intrinsically resistant or by mutational adaptations that impede drug efficacy. Intrinsic 
or acquired resistance to ITPP on the other hand is rather unlikely, as ITPP does not directly interfere 
with cancer cells. The indirect effect of ITPP on cancer cells is physicochemical and does not require 
binding sites, cellular transport, activation or other features that are relevant for conventional anti-
cancer drugs. ITPP is presumably transported into red blood cells by the anion exchanger band 3 
that is exclusively expressed on erythrocytes (106 copies per cell) and on a subset of kidney cells. 
Band 3 mutations across the population are rare and often hereditary [247-250]. Moreover, there 
are minimal species-specific differences between murine and human band 3 that should not 
impede the translation of preclinical results [251]. In line with these facts, we and other groups 
have demonstrated synergism of ITPP with chemo- and radiotherapy across a multitude of tumor 
entities [41, 242, 252, 253]. ITPP is currently being investigated in clinical trials under the name 
OXY111A. A Phase I single ascending dose clinical trial in healthy volunteers was completed 
without any safety findings and demonstrated a dose-dependent pharmacokinetic activity profile 
(unpublished data on NormOxys website). Our collaborators are conducting a prospective Phase 
Ib/IIa trial investigating the safety and efficacy of OXY111A in combination with standard 
chemotherapy in patients suffering from non-resectable primary and secondary tumors of the 
liver, pancreas and biliary tract.  One of the major limitations of ITPP treatment is the requirement 
of high doses for preclinical and clinical efficacy. In the current clinical trial the administration of 
weekly doses up to 43'500 mg/m2 ITPP are planned, which requires intravenous drug infusion over 
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several hours [254]. Therefore, future clinical trials investigating ITPP in combination with 
radiotherapy will be complicated due to the tight treatment schedule that aims to irradiate tumors 
at their maximal state of reoxygenation. 
Hemoglobin-mediated treatment mechanisms are rare and thereby impede the forecast of clinical 
ITPP-efficacy. The only other compound with a comparable mode of action is efaproxiral, which 
also reduces the hemoglobin-oxygen binding affinity resulting in enhanced tissue oxygenation 
[255]. Efaproxiral in combination with chemo- or radiotherapy modestly improved overall survival 
and quality of life in patients suffering from NSCLC or brain metastases but was not approved by 
the FDA thereafter [256-258]. The translational relevance of our proposed combination therapy 
consisting of ITPP and IR will be further strengthened by examinations in orthotopic tumor models. 
In the long term, image-guided radiotherapy of orthotopically growing tumors can be used to 
improve patient irradiation. 
4.6 Design of multimodal treatment strategies to overcome 
radioresistance 
Over the past few decades, the understanding of disease mechanisms has resulted in the 
increasing discovery of putative targets to prevent or reverse malignant progressions. Together 
with high-throughput based technologies to screen drug libraries against newly discovered disease 
targets it has led to the discovery of a plethora of clinically effective anti-cancer compounds. 
However, driven by intrinsic and acquired resistance against these agents it became evident that 
the likelihood to discover a “magic bullet” that entirely cures cancer is unrealistic. Therefore, using 
combination therapy to overcome intrinsic and prevent acquired resistance is particularly 
important in oncology. A meta-analysis of clinical trials conducted between 2008 and 2013 
revealed a higher prevalence of combination therapies in oncology (25.6%) in comparison with 
all other indications (6.9%). Moreover, it was noted that combinatorial treatments are often 
conducted as part of investigator-initiated clinical trials (e.g. by the NIH) rather than by 
pharmaceutical companies that are primarily focussed to market their own novel single agent 
products [259]. Future preclinical research and clinical trials should follow rationale-based drug 
combinations, preferably by repurposing approved drugs from other indications for the field of 
oncology. This would drastically reduce the costs and duration of clinical trials in favour of cancer 
patients and healthcare systems. Numerous approved compounds including some blockbuster-
drugs (e.g. Aspirin or Methotrexate) are promising candidates for drug repurposing in oncology 
[260]. Radiotherapy is an attractive combination partner as it acts locally and thereby prevents 
systemic toxicity. Consequently, it can be combined with systemic treatments that are associated 
with higher toxicity profiles to optimally utilize the therapeutic window.   
The novel findings of this PhD project can be used to overcome hypoxia as a major limiting factor 
of radiotherapy and combination therapies involving IR. Recent advances in cancer research are 
now shifting the focus to the field of immuno-oncology. Despite showing only modest 
improvements in overall patient survival, immune checkpoint inhibitors are being praised as new 
milestones in cancer therapeutics [120, 121, 190].  This class of molecules has undoubtedly the 
potential to perform better if certain limiting factors can be resolved. The combined treatment of 
SBRT and immune checkpoint inhibition is paradoxical since SBRT on the one hand improves 
antigen presentation but on the other hand leads to a depletion of the tumor vasculature. 
Consequently, activated lymphocytes cannot exert their cytotoxic effect since tumor infiltration is 
obstructed. We suggest a solution to overcome this controversy by pre-conditioning the TME with 
ITPP prior to combined radioimmunology treatments. ITPP-mediated vascular protection might 
preserve the integrity of tumor blood vessels and subsequently improve lymphocyte infiltration 
after SBRT. Moreover, tumor reoxygenation upon ITPP administration will enhance the cytotoxicity 
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of IR in hypoxic tumor cells. The release of tumor antigens from initially hypoxic cancer cells after 
combined ITPP and SBRT treatment will further enhance the diversity and activation of anti-
tumorigenic lymphocytes and improve tumor control when combined with immune checkpoint 
blockade. Such multimodal treatments modulating tumor hypoxia and immune cell activation for 
improved SBRT require further investigation of therapeutic dosing and scheduling. 
  
109
5. Outlook 
Tumor hypoxia is a negative prognostic factor for the efficacy of radiotherapy. An attempt to 
overcome this limitation is the use of pharmaceutical agents that modulate hypoxic tumor 
fractions prior to radiotherapy. In this PhD thesis, we demonstrate a synergistic efficacy of 
evofosfamide and myo-inositol trispyrophosphate when combined with radiotherapy. We show 
the biological mechanism of these synergies and present predictive biomarkers for therapeutic 
success. 
We and other groups demonstrated that evofosfamide is a potent radiosensitizer. We showed 
that evofosfamide requires the cellular presence of POR for bioreductive activation irrespective of 
tumor hypoxia. Based on the therapeutic failure of a registrational phase III clinical trial the patent 
holder Merck decided to discontinue further development of evofosfamide. Strong evidence 
suggests that therapeutic inefficacy was caused by a poor study design that did not consider 
patient stratification according to tumor hypoxia or POR expression. Further preclinical and clinical 
investigations with evofosfamide are therefore not expected. 
Neoadjuvant ITPP treatment significantly enhances the cytotoxicity of IR and leads to delayed 
tumor growth when compared to radiotherapy alone. This radiosensitizing effect is independent 
of the genetic cancer cell background and tumor entity. Based on that, additional efficacy-oriented 
experiments in other tumor entities will not be required. However, it will be of high importance 
to evaluate the efficacy of ITPP and image-guided SBRT in orthotopic tumors to closer mimic a 
patient irradiation setting. Preliminary experiments conducted in orthotopically growing colorectal 
liver metastases showed tumor reoxygenation upon ITPP treatment and further efficacy-oriented 
investigations with the combined treatment of ITPP and SBRT are planned. Our current 
experiments can be categorized as Proof of Concept (PoC) studies exploring whether ITPP-
mediated tumor reoxygenation leads to radiosensitization. As we successfully confirmed this 
hypothesis, future experiments could be conducted with a curative intent.  It will be interesting to 
evaluate the relevance of serial ITPP treatment in combination with fractionated radiotherapy or 
concurrent chemotherapy for tumor control and vascular protection. Furthermore, our 
mechanistic evidence strongly suggests adding an immune-checkpoint inhibitor to our treatment 
protocol as ITPP-mediated vascular protection combined with SBRT might improve the tumor 
controlling properties of immune-checkpoint blockade. 
The future development and relevance of ITPP is currently unclear as there is intriguing information 
about the patent situation. Nevertheless, we are looking forward to the outcome of the ongoing 
Phase Ia/IIb clinical trial that will decide about the future relevance of ITPP. 
In conclusion, the present PhD work illustrates tumor hypoxia as an attractive target to overcome 
radiotherapy. Pharmacological reduction or exploitation of tumor hypoxia significantly increases 
the efficacy of radiotherapy. Together with the implementation of a small-animal image-guided 
radiotherapy platform, we generated powerful data for the translation to future clinical trials. 
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